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Abstract 
Molecular chaperones, such as the 90 kDa heat-shock protein (Hsp90), 
regulate many key cellular processes and as a result have emerged as promising 
targets for drug discovery. For example, Hsp90 is responsible for folding nascent 
polypeptides associated with each of the six hallmarks of cancer, a feature that 
renders inhibition of Hsp90 unique in its ability to simultaneously disrupt multiple 
signaling cascades and selectively induce apoptosis in malignant cells. Likewise, 
cells utilize heat-shock proteins (Hsps) for the dissolution of protein aggregates 
associated with neurodegenerative diseases such as Alzheimer’s, Huntington’s, 
and Parkinson’s disease, as well as spinal and bulbar muscular atrophy (SBMA).  
Studies have shown that Hsp90 inhibitors are not only potent as anti-
cancer and neuroprotective agents, but are also well tolerated by patients. It is not 
surprising, therefore, that medicinal chemists have become interested in 
discovering new scaffolds that exhibit Hsp90 modulatory activity. Given the 
inherent diversity and vast array of scaffolds that allow for protein interaction, 
natural products have become a key component in Hsp90 drug discovery research. 
This thesis represents a discussion of the advancements made by medicinal and 
natural product chemists in the area of Hsp90 therapeutics, as well as the 
development of a novel Hsp90 inhibitory scaffold of natural product origin.  
Through utilization of a recently reported firefly luciferase assay, our 
group was able to conduct a high–throughput screen that resulted in the 
identification of several Hsp90 inhibitors that contained a 1,4-naphthoquinone 
scaffold. From this, a library of naphthoquinones was synthesized, exhibiting anti-
proliferative activities from 1.3 M to >100 M. To further probe structure–
activity relationships, a comparative molecular field analysis was performed, and 
a second generation of 1,4-naphthoquinones was developed, all of which 
exhibited anti-proliferative activities between ~1–2 M. 
Although this activity was promising, concerns arose regarding the nature 
of the scaffold itself. It is well documented that many quinone-based scaffolds 
exert non-selective cytotoxicity through formation of covalent bonds via Michael 
reaction chemistry or catalytic reduction of reactive oxygen species as a result of 
their redox activity. To circumvent this concern, the core scaffold was changed 
from a 1,4-naphthoquinone core to a structurally similar flavone core. This 
process was completed through utilization of the molecular modeling program 
AutoDock to determine the mode of binding, and was confirmed through Western 
Blot analyses. The resulting compounds exhibited anti-proliferative activities 
between 9–100 M, and displayed a unique set of biological properties previously 




 In the Robert Frost poem, “The Road Not Taken,” we learn of two paths 
diverging into a wood. The first, a simple hiking trail: flat, worn, and free of 
obstacles – this, of course, is the road taken by almost everyone. The second, 
although equal in beauty, is grassy and overgrown – we know this to be the 
demanding path, difficult and overlooked. In the poem, Frost decides to take the 
road less traveled, and says this made all the difference. 
 I have referenced this poem, in brief, because I believe that all too often in 
life, we take the path laid out in front of us simply because it’s there – it’s what 
we are “supposed to do.” It seems rare that someone has the courage to leave the 
beaten trail and pursue something that might make them truly happy, for fear of 
difficulty, change, or ill impression. I’d like to think that this thesis defines one of 
those moments – my road less traveled. And of course, in bringing this chapter of 
my life to a close, there are a number of people I would like to thank. 
 First and foremost, I would like to thank my parents, Doug and Betty, and 
my brother, Anthony. Their love and support has never faltered, and in that, have 
taught me the invaluable lesson that life is not about prestige and recognition, but 
rather about loving the experiences you are privileged to be a part of and loving 
the people you experience them with. For that, this thesis is dedicated to them. 
I would like to thank my advisor, Dr. Brian S. J. Blagg, for giving me the 
freedom and flexibility to be creative with my work, and at the same time pushing 
me to expand my productivity and knowledge beyond what I thought possible.  
I would also like to thank the Blagg lab members, all of which have 
played a part in my development as a scientist. In particular, I’d like to thank Dr. 
Jared R. Mays, Laura Peterson, and Adam Duerfeldt for their contributions to my 
work and education. 
I would like to acknowledge the members of the Medicinal Chemistry and 
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assisting with the molecular modeling experiments described herein. 
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opportunity to advance my education and professional development beyond the 
field of chemistry.  
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Chapter I: Introduction and Background 
I. An Introduction to Heat Shock Protein 90 
In recent years, molecular chaperones such as the 90 kDa heat-shock 
protein (Hsp90) have surfaced as promising targets for drug discovery.1-7 Their 
role in the folding and maturation of various client proteins, as well as the 
renaturation of misfolded proteins,8-11 makes them potential targets for many 
diseases ranging from the disruption of multiple signaling pathways associated 
with cancer1,2,4,6,12-17 to the clearance of protein aggregates in neurodegenerative 
diseases.4,5,18-23 In fact, cytotoxic inhibitors of Hsp90 are the only cancer 
chemotherapeutic agents known to impact all six hallmarks of cancer 
simultaneously.6 As defined by Hanahan and Weinberg, this includes 1) self-
sufficiency in growth signals, 2) insensitivity to antigrowth signals, 3) evasion of 
apoptosis, 4) limitless replicative potential, 5) sustained angiogenesis, and 6) 
tissue invasion/metastasis.24 Disruption of the Hsp90 protein folding machinery 
by non-cytotoxic agents promotes dissociation of heat shock factor 1 (HSF-1), 
which induces the expression of Hsp90 and facilitates the disaggregation of 













Figure 1. Structure of geldanamycin (GDA). 
 
Geldanamycin (GDA), a natural product isolated from the bacteria 
Streptomyces hygroscopicus (Figure 1), was the first identified Hsp90 inhibitor. 
Although it showed significant anti-proliferative activity against many cancer cell 
lines, its dose-limiting toxicity prevented successful completion of clinical trials. 
Since that time, a variety of natural product inhibitors of Hsp90 have emerged. 
Among these are herbimycin, radicicol, novobiocin, coumermycin A1, 
clorobiocin, epigallocatechin-3-gallate (EGCG), taxol, pochonin, derrubone, 
curcumin, gedunin, and celastrol. 
Properties of Hsp90 
Heat-shock proteins (HSPs) act as molecular chaperones, guiding nascent 
polypeptides through the process of folding and maturation into three-dimensional 
structures.26,27 Chaperones are also responsible for refolding denatured proteins 
that result from cellular stresses such as nutrient deprivation, abnormal 
temperature or pH, malignancy, and exposure to various toxins and drugs.4,28 
Heat-shock response is conserved across all species, from prokaryotes to 
eukaryotes, and provides a mechanism for the maintenance of intercellular 
processes, including protection against protein aggregation in the cytosol.29,30  
Hsp90, the most prominent of the heat-shock proteins, makes up 1–2% of 
all cellular protein8 and exists in four isoforms: Hsp90 , Hsp90 , glucose-
regulated protein (GRP94), and Hsp75/tumor necrosis factor receptor associated 
protein 1 (TRAP-1). Hsp90  and Hsp90  can be found in the cytosol, and are the 
inducible and constitutive forms, respectively. GRP94 resides in the endoplasmic 
reticulum, while TRAP-1 is located in the mitochondrial matrix.31,32 To date, 
Hsp90 has been found to interact with over 200 client proteins, as well as ~50 co-
chaperones, making it a cornerstone in the cellular protein-folding machinery and 
an emerging target for the treatment of various disease states.33,34  
Structure 
Since the first reported crystal structure by Prodromou and co-workers in 
1996,35 it has been determined that Hsp90 is comprised of three distinct structural 
domains: a 10 kDa C-terminus, 55 kDa middle domain, and a 25 kDa N-
terminus.36,37 In its biologically active form, Hsp90 exists as a homodimer bound 
in a quaternary helix bundle formed by overlapping and antiparallel pairs of 
helices from each of the C-terminal domains.38-41 C-Terminus crystal structures of 
bacterial HtpG42 and eukaryotic Hsp9043 were solved in 2004 and 2006, 
respectively. Although rumors of its existence have surfaced from industry, a co-
crystal structure of the C-terminus bound to an inhibitor has not been published. 
Csermely and co-workers first reported this binding site in 1998,44 and in 2000 
Neckers and co-workers were able to show that inhibition of Hsp90 at the C-
terminus interrupts activity in a non-ATP competitive fashion.45,46 This discovery 
has been highly influential in the development of C-terminal Hsp90 inhibitors, 
and further highlights the necessity of attaining a co-crystal structure to further 
understand this process.  
The 55 kDa middle domain of Hsp90 is the most variable region across 
species, but nonetheless is intimately involved in the binding and maturation of 
client proteins.9,38 The 25 kDa N-terminal domain is similar in structure to DNA 
gyrase B, histidine kinase, and MutL – together forming the GHKL 
(ATPase/kinase) superfamily.47 This structural homology was determined through 
domain-specific human48 and yeast49 crystal structures and eventually led to 
elucidation of the ATP-binding site at the N-terminus. A co-crystal structure with 
ADP bound in a bent conformation, characteristic of the GHKL superfamily, was 
reported soon after.50 These structures have played a critical role in the design of 
new and more efficacious Hsp90 inhibitors.51   
The Hsp90 Protein Folding Mechanism 
Under normal physiological conditions, HSF-1 is tightly bound to and 
regulated by Hsp90 in its inactive state (2a, Figure 2). Upon activation, Hsp90 
releases HSF-1, allowing translocation to the nucleus and induction of HSPs by 
binding to the heat shock response element.52 These newly formed molecular 
chaperones are then responsible for governing the folding and maturation of 
nascent and denatured polypeptides into biologically active structures. It should 
be noted that the following description of this process has been simplified for the 
purposes of this thesis.  A gamut of proteins have been linked to this folding 
mechanism, but only key interactions are highlighted herein.  
        
Figure 2. The Hsp90 protein folding mechanism. 
 
Hsp70 binds nascent polypeptides emerging from the ribosome in an ATP 
and Hsp40-dependent fashion. This complex is stabilized by Hsp70 interacting 
protein (HIP), and can be dissociated by Bcl2-associated athanogene (BAG). 
Hsp70-Hsp90 organizing protein (HOP) contains tetratricopeptide repeats (TPRs) 
recognized by both molecular chaperones, and recruitment by the Hsp70 complex 
facilitates transfer of the client protein to the Hsp90 homodimer (2b, Figure 2).53-
55 Next, several co-chaperones, partner porteins, and immunophilins, shown in 
Table 1, can bind Hsp90 (2c, Figure 2), forming a stabilized heteroprotein 
complex capable of binding ATP at the N-terminus.56-58 Upon ATP-mediated 
dimerization of the N-terminii, the activated Hsp90 multiprotein complex takes on 
a closed  “clamped” conformation, engulfing the bound client protein (2d, Figure 
2).59,60 Recruitment of p23 facilitates ATP hydrolysis (2e, Figure 2) and further 
stabilizes Hsp90,61,62 allowing for maturation and subsequent release of the client 
protein (2f, Figure 2).63 
Table 1. Co-chaperones, partner proteins, and 
immunophilins involved in the Hsp90 folding 
mechanism. 
Co-chaperones Partner Proteins Immunophilins 
Hsp40 HOP FKBP51 
Hsp70 Tom70 FKBP52 
Cdc37 PP5 Cyclophilin-40 
Aha ARA9 UNC-45 
p23 CNS1  
CHIP Dpit47  
 Tpr2  
 SGT1  
 CRN  
 WISp39  
 NASP  
 TAH1  
 Rar1  
Inhibition of Hsp90 prior to ATP-mediated dimerization (2g, Figure 2) can 
effectively destabilize the heteroprotein complex. ATP hydrolysis provides the 
energy necessary for the conformational changes that facilitate folding, 
maturation, and release of the client protein. By preventing the dimerization 
process, the Hsp90 complex is disabled, and the client becomes a substrate for 
ubiquinylation and subsequent proteasomal degradation.64,65 In a similar fashion, 
inhibition of Hsp90 can also prevent the renaturation of misfolded client proteins. 
Application of this concept has proven very useful in the renaturation of heat 
denatured firefly luciferase. A representative example by Yonehara66 has 
demonstrated that inhibition of Hsp90 reduces luciferase activity, and a 2007 
publication by Galam and co-workers used this information to establish a high-
throughput screening assay to identify both N- and C-terminal inhibitors of Hsp90 
based on the renaturation of heat denatured firefly luciferase.67  
A Selective Target for Cancer Treatment 
 Cancer is often referred to as a multifaceted class of diseases,68 dependent 
upon satisfaction of each of the six hallmarks as defined by Hanahan and 
Weinberg.24 Although many cancer chemotherapeutics have successfully targeted 
proteins associated with multiple hallmarks, none have been able to 
simultaneously affect all six. Of the numerous client proteins dependent upon 
Hsp90 for folding and maturation, many are deemed essential for malignant 
progression. Over the last ten years, Hsp90 client proteins have been linked to all 
six hallmarks of cancer (Table 2),6,14 making Hsp90 inhibition an exciting new 
chemotherapeutic target. Whitesell and Lindquist reviewed this concept in 2005,13 
and several studies and clinical trials have verified Hsp90 as a viable cancer 
target.69-71  
Table 2. The six hallmarks of cancer. 
Hallmark Hsp90 Client Proteins 
Self-sufficiency in growth signals Raf-1, AKT, Her-2, MEK, Bcr-Abl, FLT-
3, EGFR, IGF-1R, FGFR, KDR 
Insensitivity to antigrowth signals Wee 1, Myt 1, CDK4, CDK6, Plk 
Evasion of apoptosis RIP, AKT, mutant p53, c-MET, Apaf-1, 
Survivin 
Limitless replicative potential Telomerase (h-TERT) 
Sustained angiogenesis FAK, AKT, HIF-1 , VEGFR, FLT-3 
Tissue invasion/metastasis c-MET, MMP 
 
 Inhibitors of Hsp90 have shown as high as a 200-fold differential 
selectivity toward malignant versus normal cells. Several mechanisms have been 
suggested to explain this high selectivity. First, Hsp90 is significantly 
overexpressed in malignant cells to compensate for their dependency on Hsp90 
client proteins, including Her2 (ErbB2), c-Met (HGFR), Raf-1, and Akt.72-77 The 
increased concentration of Hsp90 in tumor cells inherently results in greater drug 
accumulation. A second mechanism, introduced by Conforma Therapeutics in 
2003, proposes that the Hsp90 heteroprotein complex (2c, Figure 2) exhibits a 
higher affinity for N-terminal inhibitors than the inactive homodimer (2a, Figure 
2). In cancer cells, Hsp90 exists predominantly in a heteroprotein complex due to 
the abundance of mutated, denatured, and naturally expressed proteins. In 
contrast, the primary form of Hsp90 in normal cells is the inactive homodimer, 
which explains why N-terminal inhibitors accumulate with the high-affinity 
Hsp90 complex found in tumor cells.2,78,79 Finally, a 2006 report by Duvvuri and 
co-workers80 suggests a physiochemical explanation for selectivity. Under normal 
physiological conditions, lysosomal pH is around 4–5. Hsp90 inhibitors, like 
many chemotherapeutic agents, often contain basic nitrogens, and in a process 
known as pH partitioning81 become protonated as the ammonium salt within the 
lysosome, trapping them in the organelle and preventing interaction with Hsp90, 
which resides in the cytosol. Conversely, the lysosomal pH in cancerous cells is 
essentially neutral, favoring an unprotonated amine82,83 and suggesting that the 
equilibrium drug concentration between lysosome and cytosol favors cytosolic 
interaction with tumor-derived Hsp90 (Figure 3).  
 
Figure 3. The effects of lysosomal pH on cellular drug distribution. 
 
Neurodegenerative Applications 
 Neurodegeneratvie disorders such as Alzheimer’s, Parkinson’s, 
Huntington’s, and spinal and bulbar muscular atrophy (SBMA), are in part 
characterized by the accumulation of misfolded protein aggregates. Under normal 
circumstances, this buildup can be prevented through resolubilization and 
rematuration of proteins by molecular chaperones. However, when suffering from 
these pathological conditions, aggregation exceeds the capacity of normal 
chaperone function, and can result in neuronal death.84    
Inhibition of Hsp90 stimulates the release of HSF-1, which in turn 
translocates to the nucleus, and promotes transcription of HSP mRNA, leading to 
increased synthesis of HSPs.21,25 Increased levels of Hsp70 and Hsp90 have 
shown to be inversely proportional to -amyloid and tau aggregation, and directly 
proportional to the binding of tau to microtubules, suggesting that non-cytotoxic 
inhibition of Hsp90 could serve as a neuroprotective approach for the treatment of 
Alzheimer’s disease through dissolution of protein aggregates.22 Recent studies by 
Shen and co-workers have affirmed this hypothesis by demonstrating the 
protective effects of GDA in vivo against 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced dopaminergic toxicity associated with the 
formation of Lewy bodies ( -synuclein aggregation) in a Parkinson’s disease 
model through inhibition of Hsp90.19 A similar study by Waza showed that 17-
allylamino-17-demethoxygeldanamycin (17-AAG, Figure 4), a more efficacious 
analogue of GDA, can diminish the effects of SBMA by inhibiting Hsp90, thus 
promoting degradation of mutant androgen receptor (AR) resulting from 
expansion of trinucleotide CAG repeats in the AR gene.20 Ansar and co-workers 
have produced a select number of non-toxic Hsp90 inhibitors that further 






















Figure 4. Structures of 17-AAG and AEG3482. 
 
Finally, Huntington’s, Parkinson’s, and Alzheimer’s disease attribute 
neuronal apoptosis to activation of the c-jun N-terminal kinase (JNK) signaling 
pathway. Hsp70 can attenuate this cascade by binding JNK, disrupting substrate 
interactions necessary for the initiation of apoptosis. In 2006, Gallo and co-
workers demonstrated that the imidazothiadiazole sulfonamide AEG3482 (Figure 
4) inhibits Hsp90, causing the release of HSF-1 and inducing HSP transcription. 
This in turn provides neuroprotection through Hsp70 inhibition of the JNK signal 
transduction pathway.5 Studies are underway to further refine the potential 
significance of modulating the Hsp90 protein folding machinery in a manner that 
can alleviate the accumulation of protein aggregates while providing a large 
therapeutic window that exhibits low cytotoxicity.85 
 
II. Natural Product Inhibitors of Hsp90 
 Clinical trials have shown that Hsp90 inhibitors are not only potent as 
anti-cancer agents, but are also well tolerated by patients. In fact, the toxicities 
and side effects discovered thus far have not resulted from Hsp90 inhibition, but 
rather from hepatotoxicity, gastrointestinal irritation, and constitutional 
symptoms.86,87 It is not surprising, therefore, that medicinal chemists have become 
interested in discovering new scaffolds that exhibit Hsp90 modulatory activity for 
the treatment of cancer and neurodegenerative diseases. Given the inherent 
diversity and vast array of scaffolds that allow for protein interaction, natural 
products have become a key component in Hsp90 discovery research.88 
Geldanamycin and Herbimycin 
 Geldanamycin and herbimycin (Figure 5) are naturally occurring 
benzoquinone ansamycin antibiotics that can be isolated through fermentation of 
Streptomyces hygroscopicus.89,90 The first total synthesis of herbimycin was 
reported by Nakata and co-workers in 1991.91 However, the total synthesis of 
GDA was not available until 2002, when Andrus and co-workers reported a 
procedure that afforded the product as a 1:10 mixture with (–)-o-
quinogeldanamycin in low yield.92 This result was due primarily to problematic 
oxidation of the trimethoxy precursor to the paraquinone. Andrus improved upon 
this methodology,93 and a subsequent 20 step total synthesis (2% overall yield) 
was achieved by Panek and Qin in 2008.94 
 The antitumor properties of GDA were first reported in 1986, and were 
initially attributed to its ability to inhibit v-Src phosphorylation in whole cells via 
Src tyrosine kinase.95,96 However a direct link between v-Src and GDA was never 
identified, as they were unable to directly inhibit the purified recombinant 
protein.97 This suggested there might be a non-explicit interaction between the 
kinase and GDA. In 1994, Whitesell and Neckers proved this relationship as a 
downstream effect of GDA’s ability to specifically bind and antagonize Hsp90, a 
chaperone for v-Src.98,99 Using affinity purification, immobilized GDA affixed to 
agarose beads was incubated with reticulocyte lysate, resulting in the 
identification of Hsp90. Further investigation proved that GDA specifically 
inhibited the Src/Hsp90 heteroprotein complex, facilitating degradation of the 
client protein. This observation was consistent with all prior work linking GDA to 
Src tyrosine kinase modulation. 
 Initial reports by Roe and co-workers reported that GDA acted as a 
polypeptide mimic, interacting with Hsp90 at a highly conserved, 15 Å 
polypeptide substrate binding pocket involved in protein folding and 
maturation.48,50 However, Roe’s co-crystallization of Hsp90 with GDA later 
revealed that it was actually binding to a previously unidentified ATP-binding 
pocket.100 This seminal work opened the door for structure–activity relationship 
(SAR) studies that have since led to the development of several analogues. 
 Although respectable IC50 values have been reported for GDA and 
herbimycin against various cancer cell lines, their poor solubility and 
hepatotoxicity in animals has prevented them from successfully completing 
clinical trials as anti-cancer agents.101 SAR studies have shown that modifications 
to the carbamate group of GDA can substantially decrease the potency of 
derivatives, as it serves to mimic the exocylic amino and imino nitrogens of 
adenine. A similar loss in activity can be observed upon reduction of the 2–3 
double bond, as the target–specific conformation of the macrocycle is 
compromised.88,100 Modification of the 17-methoxy substituent appears to be the 
most effective option, as it projects away from the ATP binding pocket and 
exhibits a minimal affect on Hsp90 affinity.50,102 Substituting an electron donating 
group for the 17-methoxy group decreases toxicity by stabilizing the quinone 
moiety and retarding formation of the semiquinone, which is capable of reacting 
with molecular oxygen and producing superoxide radicals.103,104  
The synthetic analogue, 17-AAG (Figure 5), produced by Schulte and 
Neckers, displayed a 100-fold increase in differential selectivity at doses similar 
to GDA, as well as decreased hepatotoxicity.105 Although 17-AAG proved to be 
more potent than GDA, solubility issues and its moderately persistent toxicity 
proved to be a factor in clinical development.106 Additional work has produced 
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG, Figure 
5), which displays lower toxicity, higher potency, and improved bioavailability 
with respect to 17-AAG.106,107 17-DMAG has entered phase I clinical trials and 
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Figure 5. Structures of geldanamycin, herbimycin, and structural analogues 17-
AAG and 17-DMAG. 
 
Since the development of 17-AAG, several analogues of GDA have 
exhibited improved antitumor properties, as well as demonstrated neuroprotective 
activity. These include bioengineered compounds developed through site-directed 
mutagenesis of the polyketide synthase gene cluster,109 semi-synthesized 
analogues resulting from biosynthetically generated metabolites,110 as well as 
several compounds arising from traditional synthetic techniques.111,112 The 
biologically modified synthetic approaches have offered alternative pathways to 
GDA analogues that were previously hindered by the lack of an efficient total 
synthesis. Traditional synthetic work, while effective, has been limited to 
alteration at the 17-position and the quinone moiety itself. 
Radicicol and Pochonin 
 To date, radicicol (RDC, Figure 6) is the most potent natural product 
inhibitor of Hsp90, manifesting an IC50 value of 23 nM.
100 Its mechanism of 
action is similar to that of GDA, in that it binds to the N-terminal ATP binding 
pocket of Hsp90. However, it does not manifest selectivity for the activated 
heteroprotein complex versus the homodimeric form, as is the case for GDA. This 
can be attributed to the more rigid structure of RDC.100,113 RDC, isolated from 
Diheterospora chlamydosporia, has proven to have many downstream oncogenic 
effects through Hsp90 inhibition, including activity against 17-AAG resistant 
retinoblastoma cells.114 However, no activity has been demonstrated in vivo, as 
RDC is rapidly metabolized to inactive structures due to the electrophilicity of the 
epoxide ring and , , , -unsaturated ketone.115 
 Several analogues of RDC have been synthesized that minimize in vivo 
metabolism by decreasing its electrophilic nature.116-121 These compounds display 
nanomolar activity in vivo. For example, synthesis of radicicol 6-oxime 
derivatives, such as KF25706 (Figure 6), has produced several compounds that 
demonstrate potent antiproliferative activity. Furthermore, the oxime 
stereochemistry has shown to be critical, as higher potency is observed with the 
E-isomer.116,117,122 Other studies have determined that Hsp90 inhibitory activity is 
dependent on the RDC scaffold being restrained to a bent conformation. This can 
be assisted by an sp2-hybridized C6 or a -oriented oxygen close in proximity to 
C10 and C12.123 However, the best resource for synthetic SAR studies has been 
the total synthesis of RDC and analogues by Danishefsky and co-workers.124 This 
route offers a notably straightforward synthesis, providing several opportunities 
for diversification. By replacing the electrophilic allylic epoxide with a 
cyclopropyl group (c-RDC, Figure 6), these researchers were able to reintroduce 














































Figure 6. Structures of radicicol, c-RDC, KF25706 and pochonin A & D. 
 
 Isolation of the structurally similar pochonin family of natural products 
from Pochonia chlamydosporia has also shown promise in Hsp90 inhibition, 
particularly with pochonin A and pochonin D.125,126 Pochonin A and D have been 
shown to directly inhibit Hsp90.126 Pochonins A–F, while themselves displaying 
cytotoxicity in the micromolar range,125 provide an opportunity for 
conformational diversity that is not as easily achieved with radicicol.127 As a 
result, several syntheses have now been reported.127,128 
Chimeric Analogues of Geldanamycin and Radicicol 
 SAR studies have shown that GDA activity is dependent upon the 
structural integrity of the quinone ring as well as the stereochemistry of the 
carbamate. Similarly, RDC activity is dependent on the resorcinol ring, and to a 
lesser extent, the epoxide.129 In addition, the amide functionality in GDA appears 

































Figure 7. Structure of the chimeric analogues of geldanamycin and radicicol. 
 
Seminal work by Shen and co-workers utilized this knowledge to compose a new 
class of chimeric analogues, combining the pro-inhibitory properties of GDA and 
RDC to form radamide, radester, and radanamycin.131-134 Each chimera improved 
upon Hsp90 inhibitory activity with respect to the parent compounds (IC50 = 42 
μM, 7.1μM, and 1.2 μM against MCF-7 breast cancer cells, respectively), and 
was synthesized in a minimal number of steps that would allow for diversification 
of this potential drug class. Early studies by this group identified the 
hydroquinone species to be more active than the corresponding quinone, which 
was later confirmed with GDA by several other research laboratories.134 
Novobiocin, Coumermycin A1, and Clorobiocin 
 The coumermycin family of antibiotics (Figure 8), isolated from 
Streptomyces spheroids, have long been used clinically for antimicrobial 
purposes.135,136 Mechanistically, they bind to the ATP binding pocket of DNA 
gyrase, another member of the GHKL superfamily,47 thus preventing ATP 
hydrolysis.137,138 Novobiocin in particular has been shown to display anti-cancer 
properties, and has been used in the clinic for many years.139 Ground breaking 
work by Neckers and co-workers demonstrated that this activity could be ascribed 
to novobiocin’s Hsp90 inhibitory activity. Using affinity chromatography, 
Neckers determined that novobiocin could competitively displace immobilized 
GDA bound to Hsp90, however GDA could not displace immobilized novobiocin 
when the reciprical experiment was performed. Further studies revealed that 
novobiocin bound to a previously unrecognized C-terminal binding pocket, and 
induced degradation of Hsp90-dependent client proteins.45,46 These studies laid 
the groundwork for a vast library of novobiocin and coumermycin analogues that 





























































Figure 8. The coumermycin family of antibiotics. 
 
 SAR studies in our lab have revealed many significant features that can 
control the activity manifested by these novobiocin analogues. Synthesis of A4 in 
2005, along with DHN1 and DHN2 in 2006 (Figure 9), highlighted key structural 
differences necessary for distinguishing between inhibition of DNA gyrase and 
Hsp90.139,140 The 4-hydroxyl and 3'-carbamate of novobiocin are critical for DNA 
gyrase activity. Removing the 4-hydroxyl moiety and hydrolysis the carbamate 
provided a 500-fold increase in selectivity for Hsp90. A methyl group at the C8 
position also moderately increased activity. As of 2006, A4 was not only the most 
potent novobiocin analogue to date, but interestingly displayed no growth 
inhibitory activity. This feature was exploited in its development as a 













































Figure 9. Structures of novobiocin analogues. 
 
 significant protection against A -induced toxicity of neurons at non-cytotoxic 
concentrations.85 Subsequent SAR studies concluded that the benzamide 
functionality of novobiocin was necessary for cytotoxicity.143,144 It was also found 
that the addition of a p-hydrogen bond acceptor and an m-aryl side chain were 
most effective in increasing anti-proliferative activity. Further derivitization 
resulting in heterocyclic analogues of the benzamide side chain revealed the most 
potent novobiocin analogue to date, KU-122. Installation of a 2-indole moiety in 
lieu of the native benzene ring resulted in a significant increase in anti-
proliferative properties (IC50 = 0.37 μM in SKBr3 breast cancer cells, 0.17 μM in 
HCT-116 colon cancer cells). This variation in activity can be credited to the 
hydrogen bond donating capability and the rigid 2,3-olefin on the indole ring. 
These novobiocin analogues are unique in that rational modification of these 
compounds can provide molecules that selectively treat bacterial infections, 
cancer, or neurodegenerative diseases. Multiple projects are currently underway 
to further elucidate these properties and to create more potent inhibitors of 
Hsp90.145  
EGCG 
 Epigallocatechin-3-gallate (EGCG, Figure 10) is a naturally occuring 
polyphenol extract from Camellia sinensis, found in green tea. Although green tea 
has been marketed in Eastern medicine for years as an anticancer agent, it wasn’t 
until 2003 that Palermo and co-workers ascribed this feature to inhibition of Aryl 
Hydrocarbon Receptor (AhR) activity.146 Shortly thereafter, affinity studies 
concluded that EGCG did not bind directly to AhR, but instead antagonized 
Hsp90. Affinity purification studies concluded that EGCG, like novobiocin, binds 










Figure 10. Structure of EGCG. 
 
More recent studies have discussed EGCG’s potential as a neuroprotective 
agent.149 Although Weinreb and co-workers attribute this property to EGCG’s 
ability to chelate iron in areas of the brain associated with Parkinson’s and 
Alzheimer’s disease, one cannot overlook the vastly growing array of Hsp90 
inhibitors known to display neuroprotective qualities. 
Taxol 
 Taxol’s (Figure 11) biological activity as an anticancer agent has been 
attributed to its stabilization of microtubles and prevention of mitosis, and has 
been used clinically for over twenty years.150 Through the activation of kinases 
and transcription factors, it has also been shown to elicit cell signaling in a 













Figure 11. Structure of taxol. 
 
Its isolation from the Pacific yew tree, Taxus brevifolia L., by Monroe Wall, and 
his subsequent discovery of its anticancer properties, stands as one of the most 
significant findings in the history of natural product research.153,154 What is 
interesting, however, is that in recent years Rosen and co-workers have been able 
to show through affinity purification studies that taxol binds Hsp90, resulting in a 
stimulatory response.155-157 This response not only sensitizes malignant tumors to 
taxol, but could even prove useful in the future development of neuroprotective 
agents. The site to which taxol binds Hsp90 has not yet been elucidated.  
Derrubone 
 Derrubone (Figure 12) is a prenylated isoflavone that was isolated from 
the Indian tree, Derris robusta, in 1969.158 A total synthesis was reported three 
years later by Jain and Jain that consisted of 14 steps.159 This feat was matched by 
Hossain and co-workers in 2006, and then improved upon by Hastings in 2007, 
reducing its preparation to 8 linear steps.160,161 Through utilization of the HTS 
luciferase assay discussed earlier,67 Hadden and co-workers identified derrubone 
as a C-terminal inhibitor of Hsp90, yielding an IC50 value of 11.9 μM against 


















Figure 12. Structure of derrubone. 
 
 SAR studies by Hastings and Hadden have identified key features of 
derrubone that allow for optimal interaction with Hsp90, and several potent 
analogues have been synthesized.160 First, the C3 aromatic ring substituent is 
essential for activity. Addition of an electron-withdrawing group at the C4  
position can further increase anti-proliferative activity, whereas substitution at C3  
results in complete loss of activity. Second, replacing the prenyl substituent with a 
more polar functionality results in decreased activity, whereas replacing it with a 
non-polar functionality gives comparable activity to the prenyl group. A slight 
increase in activity was observed when the C6 substituent was translocated to the 
C8 position. Overall, this study produced analogues with IC50 values in the low 
micromolar range, and further development of the derrubone library is currently 
underway. 
Curcumin 
Turmeric has been utilized for centuries in Ayurvedic medicine as a 
topical treatment for wounds, inflammation, and tumors.163 The active component 
was identified as curcumin (Figure 13), and its isolation from the rhizome of 
Curcuma longa L. (Zingiberaceae) over two centuries ago eventually allowed for 







Figure 13. Structure of curcumin. 
 
Properties exhibited by curcumin include anti-inflammatory, anti-oxidant, anti-
viral, cutaneous wound healing, hypocholesterolemic effects in diabetic patients, 
anti-angiogenic, and stimulatory response to stress-induced biological 
activity.165,166 Curcumin has demonstrated neuroprotective activity against A  
aggregation in Alzheimer’s models,167 and several studies have shown that 
curcumin manifests anti-proliferative activity against various cancers, including 
leukemia, colon, liver, breast, and prostate cancers.165,168-170 However, the truly 
unique feature of this molecule is its lack of toxicity. Large quantities of curcumin 
can be consumed without toxicity, suggesting this molecule may serve as a 
valuable scaffold for therapeutic development. Three phase I clinical trials have 
demonstrated tolerances as high as 12 g per day, although this is in part due to its 
poor bioavailability.171,172 These distinctive properties make curcumin a valuable 
lead compound for drug development, and it remains the focus of several clinical 
trials.173  
Recent studies in the Blagg laboratory have shown that curcumin exhibits 
its diverse range of activities through modulation of Hsp90. It was determined 
that a number of previously identified protein targets of curcumin were client 
proteins of Hsp90, and a subsequent binding study and Western Blot analysis 
confirmed that this correlation in activity was likely a result of Hsp90 inhibition. 
A major concern, however, was the potential that this activity was due to covalent 
modification of the molecular chaperone through its Michael acceptor properties, 
and not reversible binding to one of its terminii. To test this hypothesis, a number 
of analogues were synthesized that converted the electron-deficient , -
unsaturated 1,3-diketone moiety into one of two electron rich heterocycles: an 
isoxazole, which directly mimicked the 1,3-diketone central to curcumin’s core, 
or a pyrazole, which mimicked the hydrogen-bonding network of the 
corresponding enol.174 A number of analogues were synthesized, and it was 
determined that Michael acceptor properties were not critical to the retention of 
curcumin’s inhibitory activity. Furthermore, it was determined that the pyrazole 
analogues were slightly more potent than the corresponding isoxazole analogues, 
emphasizing the importance of the hydrogen-bonding network curcumin exhibits 
in its enol form. Studies are currently underway to further elucidate the interaction 
between this natural product and Hsp90.  
Gedunin and Celastrol 
In recent years, gedunin (Figure 14), a tetranotriterpenoid isolated from 
the Indian neem tree Azadirachta Indica,175 and structurally related celastrol 
(Figure 15), a quinone methide triterpene from Celastraceae family of plants, 
have become compounds of interest due to their anti-proliferative and 
neuroprotective properties.176-178 More recent studies identified these natural 
products as Hsp90 inhibitors.3,179,180 Using a connectivity map, Lamb and co-
workers were able to find high correlation scores between gedunin, celastrol, 
GDA, 17-AAG, and 17-DMAG, suggesting these natural products exhibited their 
activity through Hsp90 modulation. A subsequent paper confirmed this 
hypothesis, however a mechanism of action was not fully revealed. In a 
fluorescence polarization assay, gedunin and celastrol failed to displace GDA, 
indicating that the natural products were not binding competitively to the N-
terminal ATP-binding site. Zhang and co-workers have reported that celastrol 
may disrupt Hsp90 function by blocking interactions between the molecular 
chaperone and the co-chaperone, Cdc37, preventing formation of the Hsp90 
heteroprotein complex responsible for the maturation of Hsp90-dependent 
kinases176. Based on structural similarities between gedunin and celastrol, it is 



















Figure 14. Structures of gedunin and celastrol. 
 
 In an attempt to elucidate structure–activity relationships between the 
molecular chaperone and natural products, a semi-synthetic library has been 
synthesized.181 Although the analogues made thus far have not proven to be more 
effective than gedunin in anti-proliferation assays, Brandt and co-workers have 
identified key structural features necessary for activity.182 Steric bulk applied at 
the C7 position has a pronounced effect on anti-proliferative activity, as inhibitory 
activity is diminished in response to an increase in size. Although it appears as 
though the electronic nature of the substituent is not imperative, the presence of a 
hydrogen bond acceptor can slightly improve upon anti-proliferative properties. 
C7 substituents also exhibit an influence on the overall conformation of the 
molecule, and mediate the binding of other substituents. The olefin of the , -
unsaturated ketone is also essential for activity. One can assume this is due to the 
electrophilic nature of this moiety, however modifications to and reduction of the 
ketone itself have proven otherwise. Hydrogen bond accepting properties at the 
C3 substituent, as well as the rigidity of the 1,2-olefin are responsible for 
retention of activity. Studies are currently underway to further clarify gedunin’s 
structure–activity relationship with Hsp90. 
 
III. Summary 
 Natural products have long withstood the test of time for their 
contributions to medicinal chemistry. The development of new and interesting 
scaffolds, as well as small molecules that exhibit targeted selectivity, have been 
dependent on the isolation and modification of complex structures from Mother 
Nature. As Hsp90 continues to emerge as a promising target for the treatment of 
cancer, neurodegenerative diseases, and other disease states, the construction of 
viable inhibitors with drug-like properties becomes increasingly more important. 
The structures presented in this introduction have provided a summary of past 
achievements by natural product chemists and their recent impact on future 
applications. The remainder of this thesis will focus on a specific project 
involving the development of Hsp90 inhibitors based on the 1,4-naphthoquinone 




(1) Shimamura, T.; Shapiro, G. I. J. Thor. Oncol. 2008, 3, S152–S159. 
 
(2) Bishop, S. C.; Burlison, J. A.; Blagg, B. S. J. Curr. Canc. Drug Targ. 2007, 7, 
369–388. 
 
(3) Powers, M. V.; Workman, P. FEBS Lett. 2007, 581, 3758–3769. 
 
(4) Chaudhury, S.; Welch, T. R.; Blagg, B. S. J. ChemMedChem 2006, 1, 1331–
1340. 
 
(5) Gallo, K. A. J. Chem. Biol. 2006, 13, 115–116. 
 
(6) Zhang, H.; Burrows, F. J. Mol. Med. 2004, 82, 488–499. 
 
(7) Sreedhar, A. S.; Söti, C.; Csermely, P. Biochim. Biophys. Acta 2004, 1697, 
233–242. 
 
(8) Pratt, W. B.; Toft, D. O. Exp. Biol. Med. 2003, 228, 111–133. 
 
(9) Meyer, P.; Prodromou, C.; Hu, B.; Vaughan, C.; Roe, S. M.; Panaretou, B.; 
Piper, P. W.; Pearl, L. H. Molecular Cell 2003, 11, 647–658. 
 
(10) Chiosis, G. Expert Opin. Ther. Targets 2006, 10, 37–50. 
 
(11) Chiosis, G.; Vilenchik, M.; Kim, J.; Solit, D. Drug Discovery Today 2004, 9, 
881–888. 
(12) Csermely, P.; Schnaider, T.; Soiti, C.; Prohaszka, Z.; Nardi, G. Pharmacol. 
Ther. 1998, 79, 129–168. 
 
(13) Whitesell, L.; Lindquist, S. L. Nat. Rev. Cancer 2005, 5, 761–772. 
 
(14) Adams, J.; Elliot, P. J. Oncogene 2000, 19, 6687–6692. 
 
(15) Yufu, Y.; Nishimura, J.; Nawata, H. Leuk. Res. 1992, 16, 597–605. 
 
(16) Franzen, B.; Linder, S.; Alaiya, A. A.; Eriksson, E.; Fujioka, K.; Bergman, 
A. C. Electrophoresis 1997, 18, 582–587. 
 
(17) Luparello, C.; Noel, A.; Pucci-Minafra, I. DNA Cell Biol. 1997, 16, 1231–
1236. 
 
(18) Zou, J.; Guo, Y.; Guettouche, T.; Smith, D. F.; Voellmy, R. Cell 1998, 94, 
471–480. 
 
(19) Shen, H. Y.; He, J. C.; Wang, Y.; Huang, Q. Y.; Chen, J. F. J. Biol. Chem. 
2005, 280, 39962–39969. 
 
(20) Waza, M.; Adachi, H.; Katsuno, M.; Minamiyama, M.; Sang, C.; Tanaka, F.; 
Inukai, A.; Doyu, M.; Sobue, G. Nat. Med. 2005, 11, 1088–1095. 
 
(21) Kim, H. R.; Kang, H. S.; Kim, H. D. IUBMB Life 1999, 48, 429–433. 
 
(22) Dou, F.; Netzer, W. J.; Tanemura, K.; Li, F.; Hartl, F. U.; Takashima, A.; 
Gouras, G. K. Proc. Natl. Acad. Sci. USA 2003, 100, 721–726. 
 
(23) Dickey, C. A.; Erikson, J.; Kamal, A.; Burrows, F.; Kasibhatla, S.; Eckman, 
C. B.; Hutton, M.; Petrucelli, L. Curr. Alzheimer Res. 2005, 2, 231–238. 
 
(24) Hanahan, D.; Weinberg, A. Cell 2000, 100, 57–70. 
 
(25) Workman, P.; de Billy, E. Nature Med. 2007, 13, 1415–1417. 
 
(26) Pearl, L. H.; Prodromou, C.; Workman, P. Biochem. J. 2008, 410, 439–453. 
 
(27) Söti, C.; Nagy, E.; Giricz, Z.; Vigh, L.; Csermely, P.; Ferdinandy, P. Brit. J. 
Pharmacol. 2005, 146, 769–780. 
 
(28) Welch, W. J.; Feramisco, J. R. J. Biol. Chem. 1982, 257, 14949–14959. 
 
(29) Lindquist, S.; Craig, S. E. Annu. Rev. Genet. 1988, 22. 
 
(30) Frydman, J. Annu. Rev. Biochem. 2001, 70, 603–649. 
 
(31) Blagg, B. S. J.; Kerr, T. D. Med. Res. Rev. 2006, 26, 310–338. 
 
(32) Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; 
Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; 
Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Chem. Biol. 
2004, 11, 775–785. 
 
(33) Toft, D. O. Trends Endocrinol. Metab. 1998, 9, 238–243. 
 
(34) Picard, D. Hsp90 Interactors. 
www.picard.ch/downloads/Hsp90interactors.pdf (accessed Jul, 2008). 
 
(35) Prodromou, C.; Piper, P. W.; Pearl, L. H. Proteins: Struct. Funct. Genet. 
1996, 25, 517–522. 
 
(36) Nemoto, T. N.; Sato, N.; Iwanari, H.; Yamashita, H.; Takagi, T. J. Biol. 
Chem. 1997, 272, 26179–26187. 
 
(37) Young, J. C.; Schneider, C.; Hartl, F. U. FEBS Lett. 1997, 418, 139–143. 
 
(38) Huai, Q.; Wang, H.; Liu, Y.; Kim, H. Y.; Toft, D.; Ke, H. Structure 2005, 13, 
579–590. 
 
(39) Prodromou, C.; Panaretou, B.; Chohan, S.; Siligardi, G.; O'Brien, R.; 
Ladbury, J. E.; Roe, S. M.; Piper, P. W.; Pearl, L. H. EMBO 2000, 19. 
 
(40) Pearl, L. H.; Prodromou, C. Annu. Rev. Biochem. 2006, 75, 271–294. 
(41) Terasawa, K.; Minami, M.; Minami, Y. J. Biochem. 2005, 137, 443–447. 
 
(42) Harris, S. F.; Shiau, A. K.; Agard, D. A. Structure 2004, 12, 1087–1097. 
 
(43) Ali, M. U.; Roe, S. M.; Vaughan, C. K.; Meyer, P.; Panaretou, B.; Piper, P. 
W.; Prodromou, C.; Pearl, L. H. Nature 2006, 440, 1013–1017. 
 
(44) Söti, C.; Radics, L.; Yahara, I.; Csermely, P. Eur. J. Biochem. 1998, 255, 
611–617. 
 
(45) Marcu, M. G.; Schulte, T. W.; Neckers, L. J. Natl. Canc. Inst. 2000, 92, 242–
248. 
 
(46) Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. J. Biol. 
Chem. 2000, 275, 37181–37186. 
 
(47) Dutta, R.; Inouye, M. Trends Biochem. Sci. 2000, 25, 24–28. 
 
(48) Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; 
Pavletich, N. P. Cell 1997, 89, 239–250. 
 
(49) Prodromou, C.; Roe, S. M.; Piper, P. W.; Pearl, L. H. Nat. Struct. Biol. 1997, 
4, 477–482. 
 
(50) Prodromou, C.; Roe, S. M.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, 
L. H. Cell 1997, 90, 65–75. 
 
(51) Janin, Y. L. J. Med. Chem. 2005, 48, 7503–7512. 
 
(52) Hu, Y.; Mivechi, N. F. J. Biol. Chem. 2003, 278, 17299–17306. 
 
(53) Rutherford, S. L.; Lindquist, S. Nature 1998, 396, 336–342. 
 
(54) Carrello, A.; Ingley, E.; Minchin, R. F.; Tsai, A.; Ratajczak, T. J. Biol. Chem. 
1999, 274, 2682–2689. 
 
(55) Knight, C. A. Science 2002, 296, 2348–2349. 
 
(56) Kosano, H.; Stensgard, B.; Charlesworth, M. C.; McMahon, N.; Toft, D. J. 
Biol. Chem. 1998, 273, 32973–32979. 
 
(57) Prodromou, C.; Siligardi, G.; O'Brien, R.; Woolfson, D. N.; Regan, L.; 
Panaretou, B.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. EMBO 1999, 18, 
754–762. 
 
(58) Forsythe, H. L.; Jarvis, J. L.; Turner, J. W.; Elmore, L. W.; Holt, S. E. J. 
Biol. Chem. 2001, 276, 15571–15574. 
 
(59) Chen, S.; Sullivan, W. P.; Toft, D. O.; Smith, D. F. Cell Stress Chaperones 
1998, 3, 118–129. 
 
(60) Ratajczak, T.; Carrello, A. J. Biol. Chem. 1996, 271, 2961–2965. 
 
(61) Obermann, W. M. J.; Sondermann, H.; Russo, A. A.; Pavletich, N.; Hartl, F. 
U. J. Cell Biol. 1998, 143, 901–910. 
 
(62) Panaretou, B.; Prodromou, C.; Roe, S. M.; O'Brien, R.; Ladbury, J. E.; Piper, 
P. W.; Pearl, L. H. EMBO 1998, 17, 4829–4836. 
 
(63) Chadli, A.; Bouhouche, I.; Sullivan, W. P.; Stensgard, B.; McMahon, N.; 
Catelli, M.; Toft, D. O. Proc. Natl. Acad. Sci. USA 2000, 97, 12524–12529. 
 
(64) Wu, L. X.; Xu, J. H.; Zhang, K. Z.; Lin, Q.; Huang, X. W.; Wen, C. X.; 
Chen, Y. Z. Leukemia 2008, 22, 1402–1409. 
 
(65) Eleuteri, A. M.; Cuccioloni, M.; Bellesi, J.; Lupidi, G.; Fioretti, E.; Angeletti, 
M. Proteins: Struc. Funct. Genet. 2002, 48, 169–177. 
 
(66) Yonehara, M.; Minami, Y.; Kawata, Y.; Nagai, J.; Yahara, I. J. Biol. Chem. 
1996, 271, 2641–2645. 
 
(67) Galam, L.; Hadden, M. K.; Ma, Z.; Ye, Q.; Yun, B.; Blagg, B. S. J.; Matts, R. 
L. Bioorg. Med. Chem. 2007, 15, 1939–1946. 
 
(68) Hondermarck, H.; Tastet, C.; Yazidi-Belkoura, I. E.; Toillon, R.; Le Bourhis, 
X. J. Prot. Res. 2008, 7, 1403–1411. 
 
(69) Biamonte, M. A.; Shi, J.; Hurst, D.; Hong, K.; Boehm, M. F.; Kasibhatla, S. 
R. J. Org. Chem. 2005, 70, 717–720. 
 
(70) Martin, C. J.; Gaisser, S.; Challis, I. R.; Carletti, I.; Wilkinson, B.; Gregory, 
M.; Prodromou, C.; Roe, S. M.; Pearl, L. H.; Boyd, S. M.; Zhang, M. Q. J. 
Med. Chem. 2008, 51, 2853–2857. 
 
(71) Cortajarena, A. L.; Yi, F.; Regan, L. ACS Chem. Biol. 2008, 3, 161–166. 
 
(72) Chiosis, G.; Huezo, H.; Rosen, N.; Mimnaugh, E.; Whitesell, L.; Neckers, L. 
Mol. Cancer Ther. 2003, 2, 123–129. 
 
(73) Xu, W.; Neckers, L. Clin. Cancer Res. 2007, 13, 1625–1629. 
 
(74) Jolly, C.; Morimoto, R. I. J. Natl. Cancer Inst. 2000, 92, 1564–1572. 
 
(75) Neckers, L. Trends Mol. Med. 2002, 8, S55–S61. 
 
(76) Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-
Lorenzino, L.; Rosen, N. Chem. Biol. 2001, 8, 289–299. 
 
(77) Schnur, R. C.; Corman, M. L.; Gallaschun, R. J.; Cooper, B. A.; Dee, M. F.; 
Doty, J. L.; Muzzi, M. L.; DiOrio, C. I.; Barbacci, E. G.; Miller, P. E.; 
Pollack, V. A.; Savage, D. M.; Sloan, D. E.; Pustilnik, L. R.; Moyer, J. D.; 
Moyer, M. P. J. Med. Chem. 1995, 38, 3813–3820. 
 
(78) Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; 
Burrows, F. Nature 2003, 425, 407–410. 
 
(79) Le Brazidec, J.; Kamal, A.; Busch, D.; Thao, L.; Zhang, L.; Timony, G.; 
Grecko, R.; Trent, K.; Lough, R.; Salazar, T.; Khan, S.; Burrows, F.; Boehm, 
M. F. J. Med. Chem. 2004, 47, 3865–3873. 
 
(80) Duvvuri, M.; Konkar, S.; Hong, K. H.; Blagg, B. S. J.; Krise, J. ACS Chem. 
Biol. 2006, 1, 309–315. 
 
(81) de Duve, C.; de Barsy, T.; Poole, B.; Trouet, A.; Tulkens, P.; Van Hoof, F. 
Biochem. Pharmacol. 1974, 23, 2495–2531. 
 
(82) Altan, N.; Chen, Y.; Schindler, M.; Simon, S. M. J. Exp. Med. 1998, 187, 
1583–1598. 
 
(83) Kokkonen, N.; Rivinoja, A.; Kauppila, A.; Suokas, M.; Kellokumpu, I.; 
Kellokumpu, S. J. Biol. Chem. 2004, 279, 39982–39988. 
 
(84) Muchowski, P. J.; Wacker, J. L. Nature Rev. Neuro. 2005, 6, 11–22. 
 
(85) Ansar, S.; Burlison, J. A.; Hadden, M. K.; Yu, X. M.; Desino, K. E.; Bean, J.; 
Neckers, L.; Audus, K. L.; Michaelis, M. L.; Blagg, B. S. J. Bioorg. Med. 
Chem. Lett. 2007, 17, 1984–1990. 
 
(86) Sausville, E. A. Curr. Cancer Drug Targets 2003, 3, 377–383. 
 
(87) Banerji, U. Proc. Am. Assoc. Cancer Res. 2003, 44, 677. 
 
(88) Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. Nature Rev. Drug Disc. 
2008, 7, 608–624. 
 
(89) DeBoer, C.; Meulman, P. A.; Wnuk, R. J.; Peterson, D. H. J. Antibiot. 
(Tokyo) 1970, 23, 442–447. 
 
(90) Omura, S.; Iwai, Y.; Takahashi, Y.; Sadakane, N.; Nakagawa, A. J. Antibiot. 
1979, 32, 255–261. 
 
(91) Nakata, M.; Osumi, T.; Ueno, A.; Kimura, T.; Tamai, T.; Tatsuta, K. 
Tetrahedron Lett. 1991, 32, 6015–6018. 
 
(92) Andrus, M. B.; Hicken, E. J.; Meredith, E. L.; Simmons, B. L.; Cannon, J. F. 
Org. Lett. 2003, 5, 3859–3862. 
 
(93) Andrus, M. B.; Hicken, E. J.; Meredith, E. L.; Simmons, B. L.; Cannon, J. F. 
Org. Lett. 2003, 5, 3859–3862. 
 
(94) Qin, H.; Panek, J. S. Org. Lett. 2008, 10, 2477–2479. 
 
(95) Uehara, Y.; Hori, M.; Takeuchi, T.; Umezawa, H. Mol. Cell. Biol. 1986, 6, 
2198–2206. 
 
(96) Jove, R.; Hanafusa, H. Ann. Rev. Cell Biol. 1987, 3, 31–56. 
 
(97) Whitesell, L.; Shifrin, S. D.; Schwab, G.; Neckers, L. M. Cancer Res. 1992, 
52, 1721–1728. 
 
(98) Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. 
Proc. Natl. Acad. Sci. USA 1994, 91, 8323–8328. 
 
(99) Neckers, L.; Schulte, T. W.; Mimnaugh, E. G. Invest. New Drugs 1999, 17, 
361–373. 
 
(100) Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, 
L. H. J. Med. Chem. 1999, 42, 260–266. 
 
(101) Supko, J. G.; Hickman, R. L.; Grever, M. R.; Malspeis, L. Cancer 
Chemother. Pharmacol. 1995, 36, 305–315. 
 
(102) An, W. G.; Schnur, R. C.; Neckers, L.; Blagosklonny, M. V. Cancer 
Chemother. Pharmacol. 1997, 40, 60–64. 
 
(103) Dikalov, S.; Rumyantseva, G. V.; Piskunov, A. V.; Weiner, L. M. 
Biochemistry 1992, 31, 8947–8953. 
 
(104) Dikalov, S.; Landmesser, U.; Harrison, D. G. J. Biol. Chem. 2002, 277, 
25480–25485. 
 
(105) Schulte, T. W.; Neckers, L. M. Cancer Chemother. Pharmacol. 1998, 42, 
273–279. 
 
(106) Jez, J. M.; Chen, C.; Rastelli, G.; Stroud, R. M.; Santi, D. V. Chem. Biol. 
2003, 10, 361–368. 
 
(107) Egorin, M. J.; Lagattuta, T. F.; Hamburger, D. R.; Covey, J. M.; White, K. 
D.; Musser, S. M.; Eiseman, J. L. Cancer Chemother. Pharmacol. 2002, 49, 
7–19. 
 
(108) Wright, M. H.; Calcagno, A. M.; Salcido, C. D.; Carlson, M. D.; Ambudkar, 
S. V.; Varticovski, L. Breast Cancer Res. 2008, 10, R10. 
 
(109) Patel, K.; Piagentini, M.; Rascher, A.; Tian, Z.; Buchanan, G. O.; Regentin, 
R.; Hu, Z.; Hutchinson, C. R.; McDaniel, R. Chem. Biol. 2004, 11, 1625–
1633. 
 
(110) Lee, K.; Ryu, J. S.; Jin, Y.; Kim, W.; Kaur, N.; Chung, S. J.; Jeon, Y.; Park, 
J.; Bang, J. S.; Lee, H. S.; Kim, T. Y.; Lee, J. J.; Hong, Y. Org. Biomol. 
Chem. 2008, 6, 340–348. 
 
(111) Tadtong, S.; Meksurlyen, D.; Tanasupawat, S.; Isobe, M.; Suwanborirux, K. 
Bioorg. Med. Chem. Lett. 2007, 17, 2939–2943. 
 
(112) Maroney, A. C.; Marugan, J. J.; Mezzasalma, T. M.; Barnakov, A. N.; 
Garrabrant, T. A.; Weaner, L. E.; Jones, W. J.; Barnakova, L. A.; Koblish, H. 
K.; Todd, M. J.; Masucci, J. A.; Deckman, I. C.; Galemmo Jr., R. A.; 
Johnson, D. L. Biochemistry 2006, 45, 5678–5686. 
 
(113) Cutler, H. G.; Arrendale, R. F.; Springer, J. P.; Cole, P. D.; Roberts, R. G.; 
Hanlin, R. T. Agric. Biol. Chem. 1987, 51, 3331–3338. 
 
(114) Yamamoto, K.; Garbaccio, R. M.; Stachel, S. J.; Solit, D. B.; Chiosis, G.; 
Rosen, N.; Danishefsky, S. J. Angew. Chem. Int. Ed. 2003, 42, 371–376. 
 
(115) Geng, X.; Yang, Z.; Danishefsky, S. J. Synlett 2004, 8, 1325–1333. 
 
(116) Soga, S.; Neckers, L. M.; Schulte, T. W.; Shiotsu, Y.; Akasaka, K.; Narumi, 
H.; Agatsuma, T.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Akinaga, S. Cancer 
Res. 1999, 59, 2931–2938. 
 
(117) Agatsuma, T.; Ogawa, H.; Akasaka, K.; Asai, A.; Yamashita, Y.; 
Mizukami, T.; Akinaga, S.; Saitoh, Y. Bioorg. Med. Chem. 2002, 10, 3445–
3454. 
 
(118) Ikuina, Y.; Amishiro, N.; Miyata, M.; Narumi, H.; Ogawa, H.; Akiyama, T.; 
Shiotsu, Y.; Akinaga, S.; Murakata, C. J. Med. Chem. 2003, 46, 2534–2541. 
 
(119) Kitamura, Y.; Nara, S.; Nakagawa, A.; Nakatsu, R.; Nakashima, T.; Soga, 
S.; Kajita, S.; Shiotsu, Y.; Kanda, Y. Japan Patent WO2005063222, 2005. 
 
(120) Drysdale, M. J.; Dymock, B. W.; Barril-Alonso, X. England Patent 
WO2005034950, 2005. 
 
(121) Dymock, B. W.; Drysdale, M. J.; Fromont, C.; Jordan, A. England Patent 
WO2005021552, 2005. 
 
(122) Soga, S.; Sharma, S. V.; Shiotsu, Y.; Shimizu, M.; Tahara, H.; Yamaguchi, 
K.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Kurebayashi, J.; Schulte, T. W.; 
Neckers, L. M.; Akinaga, S. Cancer Chemother. Pharmacol. 2001, 48, 435–
445. 
 
(123) Turbyville, T. J.; Wijeratne, E. M. K.; Liu, M. X.; Burns, A. M.; Seliga, C. 
J.; Luevano, L. A.; David, C. L.; Faeth, S. H.; Whitesell, L.; Gunatilaka, A. 
A. L. J. Nat. Prod. 2006, 69, 178–184. 
 
(124) Yang, Z.; Geng, X.; Solit, D.; Pratilas, C. A.; Rosen, N.; Danishefsky, S. J. 
J. Am. Chem. Soc. 2004, 126, 7881–7889. 
 
(125) Hellwig, V.; Mayer-Bartschmid, A.; Müller, H.; Greif, G.; Kleymann, G.; 
Zitzmann, W.; Tichy, H.; Stadler, M. J. Nat. Prod. 2003, 66, 829–837. 
 
(126) Moulin, E.; Zoete, V.; Barluenga, S.; Karplus, M.; Winssinger, N. J. Am. 
Chem. Soc. 2005, 127, 6999–7004. 
 
(127) Barluenga, S.; Moulin, E.; Lopez, P.; Winssinger, N. Chem. Eur. J. 2005, 
11, 4935–4952. 
 
(128) Moulin, E.; Barluenga, S.; Winssinger, N. Org. Lett. 2005, 7, 5637–5639. 
 
(129) Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; Toft, D.; 
Neckers, L. M. Cell Stress Chaperones 1998, 3, 100–108. 
 
(130) Logan, I. R.; Gaughan, L.; McCracken, S. R. C.; Sapountzi, V.; Leung, H. 
Y.; Robson, C. N. Mol. Cell Biol. 2006, 26, 6502–6510. 
 
(131) Clevenger, R. C.; Blagg, B. S. J. Org. Lett. 2004, 2004, 4459–4462. 
 
(132) Shen, G.; Blagg, B. S. J. Org. Lett. 2005, 7. 
 
(133) Wang, M.; Shen, G.; Blagg, B. S. J. Bioorg. Med. Chem. Lett. 2006, 16, 
2459–2462. 
 
(134) Hadden, M. K.; Lubbers, D. J.; Blagg, B. S. J. Curr. Top. Med. Chem. 2006, 
6, 1173–1182. 
 
(135) Hooper, D. C.; Wolfson, J. S.; McHugh, G. L.; Winters, M. B.; Swartz, M. 
N. Antimicrob. Agents Chemother. 1982, 22, 662–671. 
 
(136) Tanitame, A.; Oyamada, Y.; Ofuji, K.; Fujimoto, M.; Suzuki, K.; Ueda, T.; 
Terauchi, H.; Kawasaki, M.; Nagai, K.; Wachi, M.; Yamagishi, J. Bioorg. 
Med. Chem. 2004, 12, 5515–5524. 
 
(137) Laurin, P.; Ferroud, D.; Schio, L.; Klich, M.; Dupuis-Hamelin, C.; Mauvais, 
P.; Lassaigne, P.; Bonnefoy, A.; Musicki, B. Bioorg. Med. Chem. Lett. 1999, 
9, 2875–2880. 
 
(138) Ali, J. A.; Jackson, A. P.; Howells, A. J.; Maxwell, A. Biochemistry 1993, 
32, 2717–2724. 
 
(139) Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. J. 
Am. Chem. Soc. 2006, 128, 15529–15536. 
 
(140) Yu, X. M.; Shen, G.; Neckers, L.; Blake, H.; Holzbeierlein, J.; Cronk, B.; 
Blagg, B. S. J. J. Am. Chem. Soc. 2005, 127, 12778–12779. 
 
(141) Burlison, J. A.; Blagg, B. S. J. Org. Lett. 2006, 8, 4855–4858. 
 
(142) Huang, Y.; Blagg, B. S. J. J. Org. Chem. 2007, 72, 3609–3613. 
 
(143) Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; 
Blagg, B. S. J. J. Org. Chem. 2008, 73, 2130–2137. 
 
(144) Donnelly, A.; Blagg, B. S. J. Curr. Med. Chem. 2008, 15, 2702–2717. 
 
(145) Donnelly, A. C.; Mays, J. R.; Burlison, J. A.; Nelson, J. T.; Vielhauer, G.; 
Holzbeierlein, J.; Blagg, B. S. J. J. Org. Chem. 2008, 73(22), 8901–8920. 
 
(146) Palermo, C. M.; Hernando, J. I. M.; Dertinger, S. D.; Kende, A. S.; 
Gasiewicz, T. A. Chem. Res. Toxicol. 2003, 16, 865–872. 
 
(147) Palermo, C. M.; Westlake, C. A.; Gasiewicz, T. A. Biochemistry 2005, 44, 
5041–5052. 
 
(148) Beltz, L. A.; Bayer, D. K.; Moss, A. L.; Simet, I. M. Anti-Cancer Agents in 
Med. Chem. 2006, 6, 389–406. 
 
(149) Weinreb, O.; Amit, T.; Youdim, M. B. H. Free Rad. Biol. Med. 2007, 43, 
546–556. 
 
(150) Schiff, P. B.; Horwitz, S. B. Proc. Natl. Acad. Sci. USA 1980, 77, 1561–
1565. 
 
(151) Ding, A. H.; Porteu, F.; Sanchez, E.; Nathan, C. F. Science 1990, 248, 370–
372. 
 
(152) Byrd, C. A.; Bornmann, W.; Erdjument-Bromage, H.; Tempst, P.; 
Pavletich, N.; Rosen, N.; Nathan, C. F.; Ding, A. Proc. Natl. Acad. Sci. USA 
1999, 96, 5645–5650. 
 
(153) Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. J. Am. 
Chem. Soc. 1971, 93, 2325–2327. 
 
(154) Kingston, D. G. I. Pharmac. Ther. 1991, 52, 1–34. 
 
(155) Basso, A. D.; Solit, D.; Chiosis, G.; Giri, B.; Tsichlis, P.; Rosen, N. J. Biol. 
Chem. 2002, 277, 39858–39866. 
 
(156) Solit, D. B.; Basso, A. D.; Olshen, A. B.; Scher, H. I.; Rosen, N. Cancer. 
Res. 2003, 63, 2139–2144. 
 
(157) Sawai, A.; Chandarlapaty, S.; Greulich, H.; Gonen, M.; Ye, Q.; Arteaga, C. 
L.; Sellers, W.; Rosen, N.; Solit, D. Cancer Res. 2008, 68, 589–596. 
 
(158) East, A. J.; Ollis, W. D.; Wheeler, R. E. J. Chem. Soc. 1969, C, 365–373. 
 
(159) Jain, A. C.; Jain, S. M. Tetrahedron 1972, 28, 5063–5067. 
 
(160) Hastings, J. M.; Hadden, M. K.; Blagg, B. S. J. J. Org. Chem. 2008, 73, 
369–373. 
 
(161) Hossain, M. M.; Kawamura, Y.; Yamashita, K.; Tsukayama, M. 
Tetrahedron 2006, 62, 8625–8635. 
 
(162) Hadden, M. K.; Galam, L.; Gestwicki, J. E.; Matts, R. L.; Blagg, B. S. J. J. 
Nat. Prod. 2007, 70, 2014–2018. 
 
(163) Sharma, R. A.; Gescher, A. J.; Steward, W. P. Eur. J. Cancer 2005, 41, 
1955–1968-1955. 
 
(164) Aggarwal, B. B.; Sundaram, C.; Malani, N.; Ichikawa, H. Adv. Exp. Med. 
Biol. 2007, 595, 1–75. 
 
(165) Goel, A.; Kunnumakkara, A. B.; Aggarwal, B. B. Biochem. Pharmacol. 
2008, 75, 787–809. 
 
(166) Joe, B.; Vijaykumar, M.; Lokesh, B. R. Crit. Rev. Food Sci. Nutr. 2004, 44, 
97–111. 
 
(167) Park, S.; Kim, D. S. H. L. J. Nat. Prod. 2002, 65, 1227–1231. 
 
(168) Wahlstrom, B.; Blennow, G. Acta. Pharmacol. Toxicol. 1978, 43, 83–87. 
 
(169) Ammon, H. P. T.; Wahl, M. A. Planta Med. 1991, 57, 1–7. 
 
(170) Rashmi, R.; Santhosh Kumar, T. R.; Karunagaran, D. FEBS Lett 2003, 538, 
19–24. 
 
(171) Cheng, A.; Hsu, C.; Lin, J.; Hsu, M.; Ho, Y.; Shen, T.; Ko, J.; Lin, J.; Lin, 
B.; Wu, M.; Yu, H.; Jee, S.; Chen, G.; Chen, T.; Chen, C.; Lai, M.; Pu, Y.; 
Pan, M.; Wang, Y.; Tsai, C.; Hsieh, C. Anticancer Res. 2001, 21, 2895–2900. 
 
(172) Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P. S. 
Planta Med. 1998, 64, 353–356. 
 
(173) Strimpakos, A. S.; Sharma, R. A. Antiox. and Redox. Sig. 2008, 10, 511–
546. 
 
(174) Amolins, M. W.; Peterson, L. B.; Blagg, B. S. J. Bioorg. Med. Chem. 2009, 
17, 360–367 
. 
(175) Khalid, S. A.; Duddeck, H.; Gonzalez-Sierra, M. J. Nat. Prod. 1989, 52, 
922–927. 
 
(176) Zhang, T.; Hamza, A.; Cao, X.; Wang, B.; Yu, S.; Zhan, C.; Sun, D. Mol. 
Canc. Ther. 2008, 7, 162–170. 
 
(177) Westerheide, S. D.; Bosman, J. D.; Mbadugha, B. N. A.; Kawahara, T. L. 
A.; Matsumoto, G.; Kim, S.; Gu, W.; Devlin, J. P.; Silverman, R. B.; 
Morimoto, R. I. J. Biol. Chem. 2004, 279, 56053–56060. 
 
(178) Uddin, S. J.; Nahar, L.; Shilpi, J. A.; Shoeb, M.; Borkowski, T.; Gibbons, 
S.; Middleton, M.; Byres, M.; Sarker, S. Phytother. Res. 2007, 21, 757–761. 
 
(179) Hieronymus, H.; Lamb, J.; Ross, K. N.; Peng, X. P.; Clement, C.; Rodina, 
A.; Nieto, M.; Du, J.; Stegmaier, K.; Raj, S. M.; Maloney, K. N.; Clardy, J.; 
Hahn, W. C.; Chiosis, G.; Golub, T. R. Cancer Cell 2006, 10, 321–330. 
 
(180) Lamb, J.; Crawford, E. D.; Peck, D.; Modell, J. W.; Blat, I. C.; Wrobel, M. 
J.; Lerner, J.; Brunet, J.; Subramanian, A.; Ross, K. N.; Reich, M.; 
Hieronymus, H.; Wei, G.; Armstrong, S. A.; Haggarty, S. J.; Clemons, P. A.; 
Wei, R.; Carr, S. A.; Lander, E. S.; Golub, T. R. Science 2006, 313, 1929–
1935. 
 
(181) Vinson-Hieronymous, H.; Golub, T. R.; Lamb, J.; Stegmaier, K. United 
States Patent WO2007117466, 2007. 
 
(182) Brandt, G. E. L.; Schmidt, M. D.; Prisinzano, T. E.; Blagg, B. S. J. J. Med. 
Chem. 2008, 51, 6495–6502. 
Chapter II: In Silico Development of a Novel  
Hsp90 Inhibition Scaffold 
I. Introduction 
 Previously, the synthesis and biological evaluation of several compounds 
based on the 1,4-naphthoquinone scaffold were described.1 A high-throughput 
screen of natural products, using the aforementioned firefly luciferase assay,2 
identified three naphthoquinone analogues that inhibited the renaturation of heat 
denatured luciferase at concentrations of ~20 μM (Table 1).  
 

















HTS1 HTS2 HTS3  
Compound Luciferase Assaya Anti-Proliferationa Her2 ELISAa 
    MCF-7 SKBr3   
HTS1 0.25 0.21 ± 0.02 0.82 ± 0.02 3.3  ± 1 
HTS2 0.38 19 ± 4 2.9 ± 0.5 1.2  ± 0.2 
HTS3 0.02 0.83 ± 0.13 0.87 ± 0.23 1.2  ± 0.3 
aData presented as IC50 concentrations in μM ± standard deviation.  
 
Upon further evaluation, these hits exhibited significant anti-proliferative activity 
against MCF-7 (ER + human breast cancer) and SKBr3 (ER -, Her2 over-
expressing human breast cancer) cell lines, and induced degradation of Her2, a 
known Hsp90-dependent client protein. These core structures provided a starting 
point for evaluation of structure–activity relationships (SAR). In total, 31 
compounds were synthesized and evaluated, and exhibited IC50 values ranging 
from 1.3 M to >100 M against MCF-7 breast cancer cells (Table 2). These 
results suggested that further evaluation would be necessary before potent 
analogues containing the 1,4-naphthoquinone scaffold could be identified as 
Hsp90 inhibitors.  
 















Compound Scaffold R1 R2 MCF-7a 
1a A CH3 H 1.6  ± 0.5 
1b A CH3 2-OMe 2.2  ± 0.7 
1c A CH3 3-OMe 2.7  ± 0.7 
1d A CH3 4-OMe 2.2 ± 0.3 
1e A CH3 2-Cl 3.0  ± 0.3 
1f A CH3 3-Cl 1.3  ± 0.5 
1g A CH3 4-Cl 1.4  ± 0.2 
1h A CH3 Benzo[b,d]furan 2.4  ± 0.3 
1i A CH3 4-OPh 2.5  ± 0.2 
2a A Ph H 2.1 ± 0.4 
2b A Ph 2-OMe 2.2 ± 0.1 
2c A Ph 3-OMe 1.4 ± 0.1 
2d A Ph 4-OMe 1.4 ± 0.02 
2e A Ph 2-Cl 1.8 ± 0.1 
2f A Ph 3-Cl 4.8 ± 2.0 
2g A Ph 4-Cl 2.6 ± 0.1 
2h A Ph Benzo[b,d]furan 6.0 ± 0.1 
2i A Ph 4-OPh 23 ± 1.9 
3 B CH3 – 1.7 ± 0.1 
4 B Ph – 1.8 ± 0.3 
5 A Biphenyl 4-OMe >100 
6 B Biphenyl – 3.0 ± 0.4 
7a A 2-Cl-Phenyl 4-OMe 2.2 ± 0.1 
7b A 3-Cl-Phenyl 4-OMe 3.4 ± 1.5 












4-OMe 1.5 ± 0.3 
7g A 1-Naphthyl 4-OMe 2.2 ± 0.3 
7h A 2-Naphthyl 4-OMe 6.8 ± 0.6 
7i A Cyclohexyl 4-OMe 1.9 ± 0.6 
aData presented as IC50 concentrations in μM ± standard deviation. 
 
 Prior to our studies, it was unknown how 1,4-naphthoquinones bind 
Hsp90, and given the shortage of Hsp90 co-crystal structures, particularly the lack 
of any C-terminal inhibitor co-crystal structure, comparative molecular field 
analysis (CoMFA) became a suitable method for further refinement of this 
scaffold.3 Three-dimensional quantitative structure–activity relationship (3D-
QSAR) studies, such as CoMFA, have played a decisive role in in silico drug 
design, although a number of limitations have been associated with this 
technique.4-6 For example, only non-covalent interactions with the binding pocket 
are evaluated during analysis, and thus covalent modifications are not considered. 
However, given the scope of our study, this approach was deemed optimal. In this 
chapter, the development of two CoMFA models based on the previously reported 
structures, as well as the design, synthesis, and biological evaluation of a second 
generation of novel naphthoquinone compounds is described. In particular, these 
models were used to probe two key structural features. First, it was necessary to 
determine the preferred cis- or trans- conformation of the amide side chain. 
Second, optimization of substituent effects within the aryl side chain was desired.  
 In a second part of this study, it was our objective to utilize the 
information compiled from the CoMFA model and biological evaluation of the 
prepared compounds to determine the mode of binding for a 1,4-naphthoquinone 
scaffold to Hsp90. A number of N- and C-terminal inhibitors of Hsp90 have been 
previously identified, and each class of compounds exhibits a unique set of 
characteristic activities that allows for mechanistic elucidation via Western Blot 
analyses3,7 (Figure 1).  
 
Figure 1. Protein lysate profile after exposure to various Hsp90 inhibitors. 
 
For example, N-terminal inhibitors not only cause Hsp90 client protein 
degradation,8,9 but they also induce concentration-dependent upregulation of 
Hsp70 and Hsp90 at the anti-proliferative IC50 concentration.
10,11 As described in 
chapter one, this property has been identified as problematic in clinical trials for 
the treatment of diseases such as cancer, where upregulation of the molecular 
chaperone can result in dosing and scheduling complications. Upregulation of 
heat shock proteins has also been identified as a physiological response to non-
cytotoxic C-terminal inhibition, however in this case client protein degradation is 
not observed within a 1000-fold increase in inhibitor concentration. This has 
proven beneficial for the potential treatment of neurodegenerative diseases, 
wherein the increased levels of molecular chaperones can assist in the dissolution 
of protein aggregates.11-15 In contrast, cytotoxic C-terminal inhibitors do not cause 
upregulation of Hsp70 and Hsp90, but do induce the degradation of Hsp90-
dependent client proteins, thereby offering a dosing regime that can be 
particularly beneficial for the treatment of cancer.16,17  
With this knowledge in hand, it therefore became critical to not only 
determine where these novel Hsp90 inhibitors bind, but also the physiological 
response exhibited by the scaffold. In terms of SAR, it is well known that many 
quinone-based structures exert non-selective cytotoxicity through formation of 
covalent bonds via Michael additions or catalytic reduction of reactive oxygen 
species as a result of their redox activity.18 In this case, having an understanding 
of the naphthoquinone mode of binding would provide an additional route for the 
development of analogues with increased potency, as well as the potential for 
removing the problematic quinone moiety without jeopardizing activity, mode of 
binding, or physiological properties of each compound. In this study, the 
naphthoquinone mode of binding was predicted by making use of the modeling 
program, AutoDock, and was confirmed through Western Blot analyses. 
AutoDock has been shown to outperform other common docking programs based 
on its descriptive algorithms and scoring function for several target proteins.19 
Developments in molecular docking over the past several years, such as with the 
program AutoDock, have provided a useful and complementary tool for 
estimating the binding energy of lead compounds, as well as for visualization of 
predicted interactions with residues in the binding pocket. From this information, 
the rational design of a library of flavone compounds, a scaffold novel to Hsp90 
inhibition, was pursued. These accounts, as well as the concluding observations, 
are discussed herein. 
 
II. Results and Discussion 
3D-QSAR/CoMFA Models and 1,4-Naphthoquinone Analogue Design 
The 31 compounds made by Hadden and co-workers1 were 
computationally aligned to produce two CoMFA models, each of which was 
generated based on one of two amide conformations, cis- or trans-, known to be 
energetically favorable for this scaffold. Compounds whose inclusion in the 
model resulted in a 3D-QSAR cross-validated correlation score (q2, leave-one-out 
technique) of less than 0.500 were considered outliers, and removed from the data 
set. In the cis-amide model, compounds HTS1, 2h, 2i, and 5 were removed, 
whereas compounds HTS2, 1e, and 7i were removed from the trans-amide model. 
Outliers were later used to validate the predictive ability of each model. 
 3D-QSAR models were derived by utilizing the modeling program 
SYBYL through a partial least squares (PLS) regression, wherein the predicted 
IC50 (pIC50) value was the dependent variable, and the calculated CoMFA 
parameters were the independent variables. In the cis-amide model (Figure 2), a 
q2 of 0.629 was observed with an optimum number of coefficients (ONC) totaling 
four. The trans-amide model yielded similar values of 0.671 and four, 
respectively.   
 
Figure 2. cis-Amide CoMFA model. 
 
These parameters were reinforced with a five-group non-cross-validation 
technique, in which the resulting correlation scores (r2) were 0.629 for the cis- 
model and 0.603 for the trans- model. Both models were derived from the 
electrostatic and hydrophobic properties of each data set. The field contributions 
for each model averaged ~30% electrostatic and ~70% hydrophobic. Additional 
statistical parameters, including the predictive ability for each model, are 
summarized in Table 3.  
Table 3.  Statistical data for 3D-QSAR CoMFA Models 
Parameters cis-Amide trans-Amide 
q2 a 0.629 0.671 
ONCb 4 4 
SEEtr
c 0.103 0.103 
r2pred
d 0.865 0.954 
Fe 38.556 130.128 
Outliersf 4 3 
Field Contribution   
Electrostatic 0.357 0.257 
Hydrophobic 0.643 0.743 
aLeave-one-out cross-validated correlation coefficient 
bOptimum number of components  
cStandard error of estimate for the training set  
dPredicted correlation coefficient for the test set  
eRatio of r2 to 1-r2   
fNumber of compounds whose inclusion results in a q2 less than 0.500 
 
 From the 3D-QSAR experiments, a number of novel 1,4-naphthoquinones 
were modeled, and pIC50 values obtained for each set of amide conformers. A 
major limitation of CoMFA is that it tolerates only very focused structural 
changes. For this reason, the SAR study was focused on the aryl side chain 
previously reported by Hadden and co-workers, as it appeared to be the most 
synthetically relevant substituent falling within the parameters of the 3D-QSAR 
models. It also allowed for a more accurate prediction of cis- and trans- amide 
pIC50 values, which was reinforced by using an acetamide side chain in all cases 
to allow for further structural consistency and optimal potency. The majority of 
compounds appeared to benefit from electron-donating substituents in the ortho- 
and para- position of the aryl side chain, although electron withdrawing 
substituents and meta-substituted aryl side chains occasionally proved beneficial. 
Furthermore, multi-substituted aryl side chains had not been previously 
investigated, and were therefore included in this study in an attempt to take 
advantage of multiple interactions with the binding pocket. From the resulting 












































































(pIC50 = 1.92 μM)
10c
(pIC50 = 2.02 μM)
10d
(pIC50 = 2.10 μM)
10e
(pIC50 = 2.57 μM)
10f
(pIC50 = 2.32 μM)
10g
(pIC50 = 2.32 μM)
10h
(pIC50 = 2.16 μM)
10i
(pIC50 = 2.24 μM)  
Scheme 1. Synthesis of 1,4-naphthoquinone analogues. 
 
1,4-Naphthoquinone Analogue Synthesis  
Chemistry previously optimized by our group was expanded upon to 
prepare a novel library of 1,4-naphthoquinones (Scheme 1). In step 1, the reduced 
nucleophilicity of the amino group in commercially available 2-amino-3-chloro-
1,4-naphthoquinone 8 required stringent conditions for acetylation. After several 
failed attempts with traditional peptide coupling techniques, it was found that the 
acetylated naphthoquinone 9 could only be afforded after stirring at reflux in 
acetyl chloride with catalytic sulfuric acid for three hours.  
Compounds 10a–10i were formed through a traditional Suzuki coupling 
reaction between 9 and the appropriate aryl boronic acid. Stirring these 
components at reflux in the presence of a catalytic amount of 
tetrakis(triphenylphosphine)palladium(0) and aqueous sodium bicarbonate in THF 
resulted in the desired products in moderate to excellent yields (51–97%).  
Evaluation of Novel 1,4-Naphthoquinones 
Table 4. Anti-proliferative activities of naphthoquinone analoguesa,b. 
Compound 
IC50             
(SKBr3) 
IC50            
(MCF-7) 
pIC50                      
(MCF-7, cis-amide) 
pIC50                 
(MCF-7, trans-amide) 
10a 3.8 ± 0.8 2.2 ± 0.4 2.309 1.944 
10b 2.76 ± 0.04 2.01 ± 0.04 1.915 2.170 
10c 2.51 ± 0.01 2.2 ± 0.1 2.019 1.717 
10d 3.1 ± 0.4 2.2 ± 0.5 2.103 1.852 
10e 5.5 ± 0.2 3.3 ± 0.3 2.570 2.673 
10f 5.1 ± 0.5 2.9 ± 0.4 2.318 1.908 
10g 3.0 ± 0.2 2.3 ± 0.2 2.320 2.477 
10h 4.4 ± 0.3 2.4 ± 0.3 2.164 1.759 
10i 3.8 ± 0.9 2.1 ± 0.1 2.238 2.669 
  
  
Correlation  Scores (R
2
): 0.612 0.069 
aAll values are in units of μM, and represent ± standard deviation for two separate experiments 
performed in triplicate. 
bpIC50 is defined as the predicted IC50 in units of  μM.  
 
The data shown in Table 4 correspond to the growth inhibitory activities 
of 1,4-naphthoquinone analogues 10a–10i against SKBr3 and MCF-7 breast 
cancer cell lines, as well as the predicted IC50 values against MCF-7 cells from 
each of the CoMFA models (cis- and trans- amide). Compounds 10b and 10i 
represent the most potent analogues, however a very flat SAR was observed for 
the entire library, which manifested low micromolar activities against both cell 
lines. Upon analysis of the anti-proliferation data, it was evident that installation 
of a multi-substituted aryl side chain, or a carefully selected mono-substituted aryl 
side chain, allowed for improved interaction in the binding pocket. In each case, 
an increase in activity compared to the previous library was observed. It also 
appeared that both hydrogen and halogen bonding interactions were possible, as 
moderate activity was observed when each type of substituent was introduced. In 
a broad sense, it appeared that improvement in activity was primarily due to 
proper control of steric constraints, as a number of small substituents were 
tolerated. It had been shown via the CoMFA model that steric bulk on the amide 
and aryl side chain resulted in a significant loss in activity. Furthermore, 
correlation scores (R2) between the experimentally determined IC50 data and the 
pIC50 values indicated that a trans-amide conformation was most likely favored in 
the binding pocket. A correlation score of 0.612 was determined for the trans 
model, whereas a score of 0.069 was reported for the cis model, indicating 
preference for the former. 
Computational and Western Blot Analysis Toward Further Analogue 
Development  
Although moderate potency had been established with the second 
generation of naphthoquinones, it was clear that further development of the 
scaffold would be necessary in order to produce activities in the nanomolar 
concentration range. Optimization of the eastern portion of the molecule appeared 
complete, and thus focus was turned to the western half for the remainder of the 
project. It was also desired at this point to remove the liabilites associated with the 
quinone moiety, while attempting to maintain a physiological profile similar to 
the 1,4-naphthoquinone scaffold. In order to accomplish this effectively, it was 
necessary to first determine the mode of binding for this class of compounds. This 
was achieved through computational analysis, utilizing the AutoDock program, 
and confirmed through Western Blot analyses.  
A recent paper by Park and co-workers described a novel class of N-
terminal Hsp90 inhibitors isolated through structure-based virtual screening.20 
These quinazolinones bear a striking resemblance to our first two libraries of 
compounds (Figure 3), and thus became an intellectual lead for development of a 




















Figure 3. Overlay of the 1,4-naphthoquinone nad quinazolinone scaffolds. 
 
The AutoDock program was used to simulate binding of compound 10d to the N-
terminal of Hsp90, using the same parameters and scoring function as those 
described in the paper by Park and co-workers. From the analysis, the lowest-
scoring molecular solvation free energy conformation was determined (-13.16 
kcal/mol, Figure 4a). An overlay of the two compounds indicated a correlative 
mode of binding (Figure 4b), justifying biological evaluation through Western 
Blot analyses.  
 
Figure 4. (a) Docking of 10d in the ATP-binding pocket of Hsp90. (b) Overlay of 
10d and a quinazolinone in the ATP-binding pocket of Hsp90. 
 
As discussed previously, each class of Hsp90 inhibitors renders a unique 
physiological profile, differentiable through Western Blot Analyses. In this case, 
compounds 10c and 10d each induced concentration-dependent upregulation of 
Hsp90, as well as concentration-dependent degradation of Her2, a known client 
protein of Hsp90 (Figure 5). This trend is a clear hallmark of N-terminal Hsp90 
inhibition. 
 
Figure 5. Western Blot analysis of protein lysates following exposure to 10c (top) 
and 10d (bottom) in MCF-7 cells (μM). Geldanamycin (500 nM) was used as a 
positive control. 
 
Design of Flavone Analogues 
Once a mode of binding had been established for the 1,4-naphthoquinone 
scaffold, it was necessary to return to the docking model for further analysis. 
Specific residue interactions were assigned by using SYBYL 7.0 to calculate the 
intermolecular distance between the ligand 10d and specific amino acid residues 
in the N-terminal crystal structure. Intermolecular distances of less than 3.5 Å 
were considered significant for potential hydrogen or halogen bonding, and 
Figure 6 represents a schematic drawing of proposed interactions between 10d 



















































Figure 6. Proposed interactions between 10d and the ATP-binding site of Hsp90. 
Hydrogen bonds are shown as dotted lines with distances given in angstroms. 
 
 
Based on this analysis, key interactions appeared to exist between the C1 carbonyl 
and the intricate hydrogen-bonding network centered about Asp93. It should be 
noted that water molecules involved in this network are highly conserved in all 
known co-crystal structures with N-terminal inhibitors, such as radicicol and 
geldanamycin, and are considered critical for binding.21,22 Hydrogen-bonding 
interactions between the C4 carbonyl and Ala55, and between the acetamide side 
chain and Gly135 via a water molecule also seemed plausible. The most 
interesting feature to note, however, was the unusual abundance of active residues 
surrounding the aryl side chain at C3. A number of amino acids in this region 
were close enough in proximity to 10d that a potential hydrogen or halogen 
bonding interaction could take place. This was in agreement with the SAR trend 
observed in our previous two libraries, and served as the starting point for the 
design of the next set of analogues. 
 In order to remove the quinone moiety, while maintaining the integrity of 
the interactions described above, a 3-acetamido-6-hydroxyflavone core was 
selected for analogue development. After inserting this scaffold into the 
previously constructed schematic, one could see that all key interactions, with the 
exception of that between the C4 carbonyl of the 1,4-naphthoquinone and Ala55, 
were conserved (Figure 7). However, with the vinylogous ester replacement, 





















































Figure 7. Proposed interactions between the newly constructed flavone scaffold 
and the ATP-binding site of Hsp90. Hydrogen bonds are shown as dotted lines 
with distances given in angstroms. 
 
 
Three dimensional analysis via AutoDock indicated that installation of a phenol at 
the C6 position would allow for additional hydrogen bonding interactions with 
Leu49 via a conserved water molecule, thereby utilizing the conserved network 
surrounding Asp93 and potentially increasing binding affinity. With respect to the 
aryl side chain, extensive investigation of SAR had been established for the 1,4-
naphthoquinone analogues, and six of those substitution patterns were selected for 
comparison with the flavone library. This included analogues corresponding to 
compounds 10a, 10c, 10d, 10h, and 10i, as well as an unsubstituted aryl ring. Due 
to synthetic barriers, which will be discussed in the next section, a 2 -methoxy 
substituent was placed in lieu of a 2 -ethoxy substituent to create an analogue 
corresponding to 10d. 
Synthesis of Flavone Analogues.  
Flavones 17a–17f were prepared through a traditional approach, beginning 
with esterification of 2-hydroxy-5-methoxymethoxyacetophenone 11 and the 
appropriate benzoyl chloride to give compounds 12a–12d in good yield (Scheme 
2). Subsequent base-mediated isomerization via a Baker–Venkataraman 











































NH21. NH4NO3, TFAA, 
AcCN, rt, 3 h
2. H2, Pd/C or PtO2 









1. AcCl, Hunig's Base
AcCN, rt, 1 h












Scheme 2. Synthesis of flavone analogues. 
 
 
Microwave-assisted cyclization yielded flavones 14a–14d, which were then Boc-
protected to give compounds 15a–15d.25 Commercially available 6-
hydroxyflavone was also submitted to Boc-protection to give compound 15e.  
Initial attempts toward installation of the acetamide side chain involved a 
3-bromo flavone intermediate that was prepared via bromination of compounds 
15a–15e using N-bromosuccinimide as a source of electrophilic bromine. The 
Boc protecting group installed in the preceding step allowed for selective 
electrophilic addition, generating products in moderate yield. This approach was 
quickly rescinded, however, when it was determined that the -bromo 
intermediate was completely inactive towards rudimentary SN
2Ar chemistry, as 
well as traditional coupling techniques, such as Ullman26 or Buchwald–Hartwig27 
conditions. This was likely due to poor electrophilicity at the C3 carbon, as it was 
positioned alpha to the carbonyl of a vinylogous ester. To overcome this obstacle, 
selective -nitration of the Boc-protected flavones 15a–15e was performed under 
mild conditions, enlisting trifluoroacetic acid anhydride and ammonium nitrate to 
afford the intermediate Boc-protected 3-nitroflavones. Reduction of the nitro 
group using 10% wt/wt Pd/C under a hydrogen atmosphere afforded anilines 16a 
and 16c–16d. It was determined that reduction of the -nitrated 2 -methoxy-5 -
chloro-flavone intermediate under the given conditions resulted in undesired 
dehalogenation, and thus, milder conditions utilizing a PtO2 catalyst were 
necessary to acquire compound 16b.28 Serendipitously, the latter technique 
provided a route to -aminated 2 -alkoxy flavones that were previously 
unattainable using the presented approach, due to their ortho- and para-directed 
activation of the aryl side chain during nitration. This observation was therefore 
exploited to synthesize compound 16f in moderate yield. In the final step, N-
acetylation followed by Boc deprotection afforded the final products, 17a–17f. 
 
 
Evaluation of Flavone Analogues 
Table 5. Growth inhibitory activities of flavone analoguesa. 
Compound IC50 (SKBr3) IC50 (MCF-7) 
17a 9.8 ± 0.6 9.4 ± 0.3 
17b 16 ± 1 19 ± 2 
17c 38 ± 4 24 ± 1 
17d 45 ± 4 >100 
17e >100 >100 
17f >100 >100 
aAll values are in units of μM, and represent ± standard error for two 
separate experiments performed in triplicate 
 
 The data shown in Table 5 represent growth inhibitory activities of 
flavone analogues 17a–17f against SKBr3 and MCF-7 breast cancer cell lines. 
Upon inspection, it became immediately apparent that the activities of the flavone 
analogues were not as desirable as those of the 1,4-naphthoquinones. However, 
the data did provide intricate SAR. In this case, the most active component of the 
library was compound 17a, which contained a 2 ,4 -dichlorophenyl side chain and 
exhibited a 9 μM IC50 concentration against both cell lines. Moderate to low 
activity in both cell lines was also observed for compounds 17b and 17c, as well 
as compound 17d (SKBr3 cells only). Although this library was small, the data 
suggests that halogen bonding is associated with the binding interactions, as each 
of the active compounds 17a–17d possess halogen-containing substituents. This is 
reinforced through comparison of compounds 17b and 17f, wherein complete loss 
in activity was observed upon removal of the 5 -chloro substituent, and also 
through compound 17e, wherein lack of aryl substitution resulted in a complete 
loss of activity. 
Initially, it was perceived that this activity was associated with the 
electron-withdrawing properties of the aryl substituents in compounds 17a–17f. 
However, one would expect that the trifluoromethyl-substituted compounds 
would display a higher binding affinity, and thus improved activity versus the 
corresponding chloro-substituted species, which was not observed. If the 
hypothesis is correct, then para- and ortho- halogen substitution is favored over 
meta-, as observed when comparing compound 17a to 17b and compound 17c to 
17d. Furthermore, as fluorine is not usually associated with halogen bonding, it is 
more likely that the trifluoromethyl group is actually involved in hydrogen-
bonding interactions.29 
Western Blot analyses confirmed that compounds 17a and 17b induced a 
concentration-dependent heat shock response that reciprocated their cytotoxicity 
profile (Figure 8). As previously discussed, this is a property associated with anti-
proliferative N-terminal inhibition of Hsp90. However, to our surprise the 
corresponding concentration-dependent degradation of client proteins was not 
observed. Typically, a lysate profile of this nature is associated with 
neuroprotective inhibitors of Hsp90. However, whereas the nueroprotective 
inhibitors are non-toxic, this scaffold clearly exhibits toxicity, and as such 
suggests a physiological profile previously unidentified for Hsp90 modulators.  
 
Figure 8. Western Blot analysis of protein lysates following exposure to 17a (top) 
and 17b (bottom) in MCF-7 cells. 
 
In light of this observation, it is unclear how these compounds induce Hsp 
expression and cell death without induction of client protein degredation. As a 
result, further biological investigation will be required to elucidate the mechanism 
of action manifested by these compounds. 
 
III. Conclusions 
 As Hsp90 continues to emerge as a promising target for the treatment of 
cancer, neurodegenerative diseases, and other disease states, the construction of 
viable inhibitors with drug-like properties will become increasingly more 
important. Using traditional chemical, biological, and computational techniques, 
two novel scaffolds were developed, and their mode of action probed. Where it 
was apparent that the 1,4-naphthoquinone scaffold inhibits Hsp90 via the N-
terminus, the corresponding flavone scaffold exhibits a unique set of biological 
properties, making determination of its mechanism of action unclear at present. 
Additional studies will be needed to further understand the attributes possessed by 
the scaffolds, and perhaps, the intricate mechanism of Hsp90 modulation. 
 
IV. Experimental Section 
General Methods  
Unless otherwise indicated, all reagents were purchased from commercial 
suppliers and were used without further purification. All stir bars and glassware 
were flame-dried, and glassware was flushed with argon immediately prior to use. 
The 1H and 13C NMR spectra were recorded at 500 and 125 MHz, respectively, on 
a Bruker DRX 500 using the indicated solvents,  in ppm, and J (Hz) assignments 
of resonance coupling. Column chromatography was performed with silica gel 
(40–63 μm particle size) from Sorbent Technologies (Atlanta, GA). Analytical 
HPLC was carried out on an Agilent 1100 series capillary HPLC system with 
diode array detection at 209 nm (naphthoquinones) or 254 nm (flavones) on a 
Phenomenex Luna C18 column (10 x 250 mm, 5 μm) with isocratic elution in 
60% acetonitrile and 40% H2O at a flow rate of 5.0 mL/min. 
CoMFA Models and in silico Analysis (AutoDock) 
A training set of 31 compounds was compiled from a paper by Hadden 
and co-workers.1 The biological data (IC50 values: drug concentration in μM) 
were obtained through methods described below, and converted into pIC50 (-
logIC50) values. This data was used as an independent variable in the CoMFA 
analyses. Molecular structures were built using SYBYL 7.0 on a Silicon Graphics 
02 workstation under the IRIX Release 6.5 operating system, and energy 
minimizations were performed using the Tripos force field utilizing a distance-
dependent dielectric function. After minimization, manual manipulation of the 
amide bond, followed by minimization with limited convergence criterion (NB 
cutoff set to 1.0 Å), was performed to provide both a cis and trans amide library.  
Atomic charges were calculated using Gasteiger-Marsili methodology. 
Molecular alignment of each amide library was performed using the database 
alignment feature of SYBYL 7.0, using the Hadden compound 1a and the core 
naphthoquinone scaffold as a reference. CoMFA models were constructed based 
on electrostatic and hydrophobic field energies calculated through SYBYL 
(default settings) and the Tripos force field. All grid point calculations were 
completed using an sp3 hybridized carbon atom with a +1.0 charge and a van der 
Waals radius of 1.52 Å as a probe. 
 3D-QSAR models were derived with SYBYL through a partial least 
squares regression, where pIC50 was the dependent variable, and the calculated 
CoMFA parameters were the independent variables. These models were 
confirmed through a leave one out cross-validation technique, where specific 
compounds were either removed or region-focused to offer the highest possible q2 
value. Non-cross-validation was used to reinforce this, sighting r2 for accuracy. 
Upon validation, each model was used to predict pIC50 values in the development 
of the naphthoquinones described in this paper. 
 The AutoDock program was used to simulate binding of compound 10d to 
the N-terminal of Hsp90. The coordinates in the co-crystal structure of Hsp90 and 
a benzenesulfonamide inhibitor (PBD: 2BZ5) were used for the receptor 
molecule, while the energy-minimized structure generated from the previous 
CoMFA study was selected for 10d. During the simulation, the default AutoDock 
scoring function was used,19 incorporating van der Waals, hydrogen bonding, and 
electrostatic interactions, as well as torsional and ligand desolvation factors. From 
the resulting analysis, the lowest-scoring molecular solvation free energy 
conformation was selected for each ligand. Protein-ligand hydrogen bonding 
interactions were determined through a 3D analysis of the model, wherein 
intermolecular distances of less than 3.5 Å were considered significant for 
potential hydrogen bonding interactions. Overlay of the protein-ligand complex 
and CoMFA was achieved by introducing both models of compound 10d into the 
same molecular area, and using the Match algorithm associated with SYBYL 7.0. 
Analogue Synthesis 
N-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)acetamide (9). 2-
Amino-3-chloro-1,4-naphthoquinone (8, 5.000 g, 24.08 mmol) was dissolved in 
acetyl chloride (150 mL) and stirred at rt. A catalytic amount of concentrated 
sulfuric acid (625 L) was added at rt. The solution heated to reflux and stirred 
for 3 h. The solvent was removed, and the residue was partitioned between EtOAc 
(200 mL) and H2O (200 mL). The organic layer was washed with saturated 
aqueous sodium chloride (2 x 200 mL), dried (Na2SO4), filtered, and concentrated 
in vacuo. The residue was purified by column chromatography (SiO2, 20:3 
hexanes:EtOAc, then 20:9 hexanes:EtOAc) to afford 9 (1.25 g, 18%) as a yellow 
amorphous solid: 1H NMR (DMSO-d6, 500 MHz)  8.06 (m, 1H), 8.02 (m, 1H), 
7.89 (m, 2H), 2.13 (s, 3H); 13C NMR (DMSO-d6, 125 MHz)  178.8, 177.6, 168.0, 
141.3, 134.55, 134.52, 131.0, 130.8, 126.7, 126.6 (2C); IR (film) max 3310, 3250, 
2359, 2341, 1711, 1693, 1661, 1609, 1587, 1479, 1456, 1427, 1375, 1327, 1312, 
1294, 1254, 1223, 1198, 1169, 1126, 1051, 1038, 1022, 986, 964 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C12H8NO3Cl 250.0271; found 250.0275. 
N-(3-(2,4-Dichlorophenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)acetamide (10a). A solution of 9 (20.0 mg, 0.068 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (6 mol%, 4.75 mg, 4.11 mol) in 
THF:2M K2CO3 (10:1, 4.4 mL) stirred at rt for 30 min. 2,4-Dichlorophenyl 
boronic acid (39.19 mg, 0.21 mmol) was added and the solution stirred for 30 min 
at rt, then heated to reflux 15 hr. The solution was cooled, filtered through celite, 
and diluted with EtOAc (50 mL). The organic layer was washed with H2O (50 
mL) and saturated aqueous sodium chloride (50 mL), dried (Na2SO4), filtered, and 
concentrated. The residue was purified by column chromatography (SiO2, 20:1 
hexanes:EtOAc) to afford 10a (14.8 mg, 60%) as a yellow amorphous solid: 1H 
NMR (CDCl3, 500 MHz)  8.16 (m, 2H), 7.98 (bs, N-H), 7.79 (m, 2H), 7.48 (d, J 
= 2.1 Hz, 1H), 7.31 (dd, J = 8.3, 2.1 Hz, 1H), 7.19 (d, J = 8.3 Hz, 1H), 2.07 (s, 
3H); 13C NMR (CDCl3, 125 MHz)  182.2, 181.9, 166.5, 138.3, 134.9, 134.0, 
133.7, 132.2, 131.6, 130.9, 130.2, 129.4, 127.2, 126.7, 126.5 24.1; IR (film) max 
3292, 1701, 1668, 1618, 1587, 1555, 1491, 1472, 1425, 1369, 1329, 1294, 1236, 
1205, 1188, 1159, 1144, 1101, 1059, 1041, 1013, 987, 974, 943 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C18H11NO3Cl2 360.0194; found 360.0182. 
N-(3-(2,5-Dichlorophenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)acetamide (10b). A solution of 9 (20.0 mg, 0.068 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (4 mol%, 3.17 mg, 2.74 mol) in 
THF:2M K2CO3 (10:1, 4.4 mL) stirred at rt for 30 min. 2,5-Dichlorophenyl 
boronic acid (32.66 mg, 0.17 mmol) was added and the solution stirred for 30 min 
at rt, then heated to reflux for 15 hr. The solution was cooled, filtered through 
celite, and diluted with EtOAc (50 mL). The organic layer was washed with H2O 
(50 mL) and saturated aqueous sodium chloride (50 mL), dried (Na2SO4), filtered, 
and concentrated. The residue was purified by column chromatography (SiO2, 
20:1 hexanes:EtOAc) to afford 10b (12.6 mg, 51%) as a yellow amorphous solid: 
1H NMR (CDCl3, 500 MHz)  8.17 (m, 2H), 8.00 (bs, N-H), 7.79 (m, 2H), 7.41 
(d, J = 8.6 Hz, 1H), 7.29 (dd, J = 8.6, 2.5 Hz, 1H), 7.21 (d, J = 2.5 Hz, 1H), 2.08 
(s, 3H); 13C NMR (CDCl3, 125 MHz)  181.90, 181.88, 166.5, 138.2, 135.1, 
134.8, 133.7, 132.2, 132.1, 132.0, 130.5, 130.4, 130.1, 130.0, 127.2, 126.6 (2C), 
24.2; IR (film) max 3290, 2922, 2851, 1668, 1618, 1593, 1493, 1464, 1383, 1294, 
1234, 1205, 1159, 1097, 1041, 1016 cm-1; HRMS(ES+) m/z: [M+H] calcd for 
C18H11NO3Cl2 360.0194; found 360.0197. 
N-(3-(5-Chloro-2-methoxyphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)acetamide (10c). A solution of 9 (20.0 mg, 0.068 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (4 mol%, 3.17 mg, 2.74 mol) in 
THF:2M K2CO3 (10:1, 4.4 mL) stirred at rt for 30 min. 5-Chloro-2-
methoxyphenyl boronic acid (25.52 mg, 0.14 mmol) was added and the solution 
stirred for 30 min at rt, then heated to reflux for 15 hr. The solution was cooled, 
filtered through celite, and diluted with EtOAc (50 mL). The organic layer was 
washed with H2O (50 mL) and saturated aqueous sodium chloride (50 mL), dried 
(Na2SO4), filtered, and concentrated. The residue was purified by column 
chromatography (SiO2, 9:1 hexanes:EtOAc) to afford 10c (22.1 mg, 91%) as a 
yellow–orange amorphous solid: 1H NMR (CDCl3, 500 MHz)  8.13 (d, J = 7.25 
Hz, 2H), 7.82 (bs, N-H), 7.76 (m, 2H), 7.31 (dd, J = 8.9, 2.6 Hz, 1H), 7.05 (d, J = 
2.6 Hz, 1H), 6.95 (d, J = 8.9 Hz, 1H), 3.84 (s, 3H), 2.05 (s, 3H); 13C NMR 
(CDCl3, 125 MHz)  182.2, 181.8, 166.9, 155.7, 138.5, 134.6, 133.4, 132.4, 
132.0, 130.4, 129.9, 128.7, 127.0, 126.4, 125.2, 124.6, 112.6, 56.3, 24.0; IR (film) 
max 3292, 3070, 2959, 2935, 2849, 1693, 1666, 1618, 1593, 1487, 1441, 1396, 
1369, 1339, 1294, 1269, 1250, 1202, 1180, 1159, 1142, 1111, 1016 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C19H14NO4Cl 356.0690; found 356.0687. 
N-(3-(2-Ethoxyphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)acetamide (10d). A solution of 9 (20.0 mg, 0.068 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (4 mol%, 3.17 mg, 2.74 mol) in 
THF:2M K2CO3 (10:1, 4.4 mL) stirred at rt for 30 min. 2-Ethoxyphenyl boronic 
acid (22.72 mg, 0.14 mmol) was added and the solution stirred for 30 min at rt, 
then heated to reflux for 15 hr. The solution was cooled, filtered through celite, 
and diluted with EtOAc (50 mL). The organic layer was washed with H2O (50 
mL) and saturated aqueous sodium chloride (50 mL), dried (Na2SO4), filtered, and 
concentrated. The residue was purified by column chromatography (SiO2, 9:1 
hexanes:EtOAc) to afford 10d (19.1 mg, 83%) as an orange amorphous solid: 1H 
NMR (CDCl3, 500 MHz)  8.15 (m, 2H), 7.75 (m, 2H), 7.65 (bs, N-H), 7.38 (dt, J 
= 7.9, 1.7 Hz, 1H), 7.16 (dd, J = 7.9, 1.8 Hz, 1H), 7.02 (t, J = 7.8 Hz, 2H), 4.17 
(m, 1H), 4.05 (m, 1H), 2.02 (s, 3H), 1.31 (t, J = 7.0 Hz); 13C NMR (CDCl3, 125 
MHz)  183.1, 181.4, 167.5, 156.0, 139.2, 134.2, 133.3, 132.5, 131.1, 130.5, 
130.4, 126.8, 126.4, 122.0, 120.4, 112.5, 64.4, 23.7, 14.8; IR (film) max 3323, 
3304, 3285, 3246, 3186, 3067, 2978, 2928, 2361, 2343, 1664, 1616, 1597, 1578, 
1491, 1475, 1448, 1420, 1387, 1367, 1344, 1327, 1296, 1286, 1269, 1246, 1202, 
1159, 1122, 1109, 1088, 1043, 1013, 989, 970, 922, 905 cm-1; HRMS(ES+) m/z: 
[M+H] calcd for C20H17NO4 336.1236; found 336.1249. 
N-(3-(2,3-Dimethoxyphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)acetamide (10e). A solution of 9 (20.0 mg, 0.068 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (6 mol%, 4.75 mg, 4.11 mol) in 
THF:2M K2CO3 (10:1, 4.4 mL) stirred at rt for 30 min. 2,3-Dimethoxyphenyl 
boronic acid (37.38 mg, 0.21 mmol) was added and the solution stirred for 30 min 
at rt, then heated to reflux for 15 hr. The solution was cooled, filtered through 
celite, and diluted with EtOAc (50 mL). The organic layer was washed with H2O 
(50 mL) and saturated aqueous sodium chloride (50 mL), dried (Na2SO4), filtered, 
and concentrated. The residue was purified by column chromatography (SiO2, 
20:1 hexanes:EtOAc) to afford 10e (22.8 mg, 95%) as a yellow amorphous solid: 
1H NMR (CDCl3, 500 MHz)  8.16 (m, 2H), 7.77 (m, 2H), 7.71 (bs, N-H), 7.13 (t, 
J = 8.0 Hz, 1H), 7.00 (dd, J = 8.2, 1.4 Hz, 1H), 6.77 (dd, J = 7.8, 1.4 Hz, 1H), 
3.92 (s, 3H), 3.79 (s, 3H), 2.05 (s, 3H); 13C NMR (CDCl3, 125 MHz)  183.6, 
181.0, 167.9, 152.5, 146.3, 139.8, 134.21, 134.17, 133.6, 132.4, 131.3, 126.8, 
126.6, 126.5, 123.8, 122.3, 113.2, 61.2, 55.7, 23.7; IR (film) max 3292, 3285, 
3258, 2930, 2853, 2837, 1666, 1647, 1618, 1595, 1578, 1474, 1425, 1400, 1367, 
1346, 1325, 1290, 1265, 1236, 1223, 1169, 1161, 1124, 1084, 1065, 1041, 1003, 
920, 906 cm-1; HRMS(ES+) m/z: [M+H] calcd for C20H17NO5 352.1185; found 
352.1192. 
N-(3-(2,4-Dimethoxyphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)acetamide (10f). A solution of 9 (20.0 mg, 0.068 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (4 mol%, 3.17 mg, 2.74 mol) in 
THF:2M K2CO3 (10:1, 4.4 mL) stirred at rt for 30 min. 2,4-Dimethoxyphenyl 
boronic acid (24.91 mg, 0.14 mmol) was added and the solution stirred for 30 min 
at rt, then heated to reflux for 15 hr. The solution was cooled, filtered through 
celite, and diluted with EtOAc (50 mL). The organic layer was washed with H2O 
(50 mL) and saturated aqueous sodium chloride (50 mL), dried (Na2SO4), filtered, 
and concentrated. The residue was purified by column chromatography (SiO2, 5:1 
hexanes:EtOAc) to afford 10f (23.4 mg, 97%) as a red amorphous solid: 1H NMR 
(CDCl3, 500 MHz)  8.12 (dd, J = 7.0, 1.9 Hz), 7.73 (m, 2H), 7.61 (bs, N-H), 7.06 
(d, J = 8.4 Hz), 6.56 (m, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 2.02 (s, 3H); 13C NMR 
(CDCl3, 125 MHz)  183.2, 181.6, 161.7, 157.8, 139.0, 134.2, 134.1, 133.3, 
132.5, 130.97, 130.91, 126.8, 126.3, 114.4, 104.9, 98.9, 55.9, 55.3, 23.7; IR (film) 
max 3304, 3294, 3188, 3067, 3001, 2959, 2935, 2839, 1664, 1604, 1605, 1578, 
1504, 1491, 1466, 1458, 1439, 1416, 1367, 1342, 1296, 1275, 1261, 1209, 1184, 
1159, 1140, 1132, 1105, 1084, 1034, 1014, 989, 935, 921 cm-1; HRMS(ES+) m/z: 
[M+H] calcd for C20H17NO5 352.1185; found 352.1181. 
 N-(3-(2,5-Dimethoxyphenyl)-1,4-dioxo-1,4-dihydronaphthalen-2-
yl)acetamide (10g). A solution of 9 (20.0 mg, 0.068 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (4 mol%, 3.17 mg, 2.74 mol) in 
THF:2M K2CO3 (10:1, 4.4 mL) stirred at rt for 30 min. 2,5-Dimethoxyphenyl 
boronic acid (24.91 mg, 0.14 mmol) was added and the solution stirred for 30 min 
at rt, then heated to reflux for 15 hr. The solution was cooled, filtered through 
celite, and diluted with EtOAc (50 mL). The organic layer was washed with H2O 
(50 mL) and saturated aqueous sodium chloride (50 mL), dried (Na2SO4), filtered, 
and concentrated. The residue was purified by column chromatography (SiO2, 3:1 
hexanes:EtOAc) to afford 10g (22.5 mg, 94%) as a red amorphous solid: 1H NMR 
(CDCl3, 500 MHz)  8.13 (m, 2H), 7.75 (m, 2H), 7.66 (bs, N-H), 6.97 (d, J = 9.0 
Hz, 1H), 6.93 (dd, J = 9.0, 2.95 Hz, 1H), 6.69 (d, J = 2.95 Hz, 1H), 3.81 (s, 3H), 
3.77 (s, 3H), 2.04 (s, 3H); 13C NMR (CDCl3, 125 MHz)  182.8, 181.5, 167.4, 
153.3, 151.0, 139.1, 134.4, 133.8, 133.4, 132.5, 130.9, 126.9, 126.4, 122.9, 115.5, 
115.3, 112.6, 56.6, 55.7, 23.8; IR (film) max 3292, 2997, 2941, 2833, 1666, 1595, 
1580, 1499, 1468, 1421, 1369, 1342, 1327, 1283, 1269, 1252, 1225, 1200, 1180, 
1159, 1099, 1082, 1043, 1018, 949, 920 cm-1; HRMS(ES+) m/z: [M+H] calcd for 
C20H17NO5 352.1185; found 352.1179. 
 N-(1,4-Dioxo-3-(2-(trifluoromethyl)phenyl)-1,4-dihydronaphthalen-2-
yl)acetamide (10h). A solution of 9 (20.0 mg, 0.068 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (4 mol%, 3.17 mg, 2.74 mol) in 
THF:2M K2CO3 (10:1, 4.4 mL) stirred at rt for 30 min. 2-Trifluoromethylphenyl 
boronic acid (39.01 mg, 0.21 mmol) was added and the solution stirred for 30 min 
at rt, then heated to reflux for 15 hr. The solution was cooled, filtered through 
celite, and diluted with EtOAc (50 mL). The organic layer was washed with H2O 
(50 mL) and saturated aqueous sodium chloride (50 mL), dried (Na2SO4), filtered, 
and concentrated. The residue was purified by column chromatography (SiO2, 9:1 
hexanes:EtOAc) to afford 10h (15.2 mg, 62%) as a yellow amorphous solid: 1H 
NMR (CDCl3, 500 MHz)  8.87 (m, 2H), 7.78 (m, 2H), 7.75 (d, J = 7.8 Hz, 1H), 
7.71 (bs, N-H), 7.59 (t, J = 7.6 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.28 (d, J = 7.7 
Hz, 1H), 2.01 (s, 3H); 13C NMR (CDCl3, 125 MHz)  183.2, 181.8, 166.6, 137.7, 
134.9, 133.9, 133.7, 132.0, 131.5, 131.1, 130.4, 128.7, 127.2, 126.6, 126.5, 125.3, 
123.1, 24.0; IR (film) max 3308, 3069, 1695, 1670, 1616, 1595, 1491, 1481, 1447, 
1369, 1317, 1292, 1263, 1240, 1205, 1171, 1119, 1059, 1036, 1014, 989 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C19H12NOF3 360.0847; found 360.0860. 
N-(1,4-dioxo-3-(3-(trifluoromethyl)phenyl)-1,4-dihydronaphthalen-2-
yl)acetamide (10i). A solution of 9 (20.0 mg, 0.068 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (4 mol%, 3.17 mg, 2.74 mol) in 4.4 
mL THF:2M K2CO3 (10:1) stirred at rt for 30 min. 3-Trifluoromethylphenyl 
boronic acid (39.01 mg, 0.21 mmol) was added and the solution stirred for 30 min 
at rt. The solution was heated to reflux and stirred for 15 hr. The solution was 
cooled, filtered through celite, and diluted with EtOAc (50 mL). The EtOAc was 
washed with H2O (50 mL) and saturated aqeous sodium chloride (50 mL), dried 
(Na2SO4), filtered, and concentrated. The residue was purified by column 
chromatography (SiO2, 20:1 hexanes:EtOAc) to afford 10i (23.7 mg, 96%) as a 
yellow amorphous solid: 1H NMR (CDCl3, 500 MHz)  8.16 (m, 2H), 7.92 (bs, 
N-H), 7.79 (m, 2H), 7.60 (m, 4H) 2.01 (s, 3H); 13C NMR (CDCl3, 125 MHz)  
182.9, 182.2, 166.2, 137.3, 135.0, 134.4, 133.7, 133.3, 132.5, 132.1, 130.3, 130.1, 
128.4, 127.1, 126.4, 126.4, 125.2, 125.0, 24.0; IR (film) max 3000, 1695, 1666, 
1595, 1477, 1458, 1431, 1371, 1342, 1325, 1294, 1269, 1236, 1205, 1167, 1124, 
1097, 1072, 1045, 1018 cm-1; HRMS(ES+) m/z: [M+H] calcd for C19H12NOF3 
360.0847; found 360.0848. 
1-(2-Hydroxy-5-(methoxymethoxy)phenyl)ethanone (11). 2’,5’-
Dihydroxyacetophenone (5.000 g, 32.86 mmol) and triethylamine (5.50 mL, 
39.43 mmol) were dissolved in THF (100 mL) and stirred at rt. Methoxymethyl 
chloride (6.26M in MeOH, 10.50 mL, 65.72 mmol) was added dropwise, and the 
solution subsequently stirred at reflux for 48 h. The solution was quenched with 
H2O (100 mL), and the aqueous layer was then extracted with EtOAc (3 x 50 
mL). The combined organic layers were washed with saturated aqueous NaHCO3 
and saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2,9:1Hexanes:EtOAc) to afford 
11 (6.447 g, 80%) as a yellow oil: 1H NMR (CDCl3, 500 MHz)  11.92 (s, 1H), 
7.38 (d, J = 2.95 Hz, 1H), 7.21 (dd, J = 9.05 Hz, 2.95 Hz, 1H), 6.90 (d, J = 9.05 
Hz, 1H), 5.12 (s, 2H), 3.49 (s, 3H), 2.61 (s, 3H); 13C NMR (CDCl3, 125 MHz)  
204.1, 157.5, 149.2, 126.3, 119.2, 119.1, 117.0, 95.4, 55.9, 26.7; IR (film) max 
3254, 3045, 2997, 2955, 2903, 2847, 2827, 2789, 1645, 1620, 1585, 1485, 1427, 
1404, 1367, 1321, 1288, 1248, 1211, 1192, 1153, 1080, 1011, 962, 922 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C10H12O4 196.0736; found 197.0781. 
2-Acetyl-4-(methoxymethoxy)phenyl 2,4-dichlorobenzoate (12a). 
Compound 11 (1.000 g, 5.10 mmol) was dissolved in pyridine (1.5 mL) and 
stirred at rt. 2,4-Dichlorobenzoyl chloride (0.78 mL, 5.61 mmol) was added 
dropwise, and the solution stirred for 10 min at 75ºC. The solution was poured 
into 3M HCl (6 mL) at 0ºC, and the aqueous layer was extracted with EtOAc. The 
combined organic layers were dried (Na2SO4), filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 17:3 Hexanes:EtOAc to 1:1 
Hexanes:EtOAc) to afford 12a (1.78 g, 94%) as a pale yellow amorphous solid: 
1H NMR (CDCl3, 500 MHz)  8.13 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 
7.51 (d, J = 2.95 Hz, 1H), 7.40 (dd, J = 8.4, 2.0 Hz, 1H), 7.27 (dd, J = 8.8, 2.95 
Hz, 1H), 7.16 (d, J = 8.8 Hz, 1H), 5.22 (s, 2H), 3.50 (s, 3H), 2.54 (s, 3H); 13C 
NMR (CDCl3, 125 MHz)  197.1, 163.3, 155.0, 142.8, 139.0, 135.5, 133.2, 131.1 
(2C), 127.3, 127.2, 124.7, 120.9, 117.9, 94.6, 56.1, 29.1; IR (film) max 3094, 
2957, 2934, 2905, 2827, 1751, 1690, 1583, 1556, 1489, 1472, 1441, 1418, 1404, 
1377, 1358, 1315, 1273, 1238, 1204, 1184, 1153, 1088, 1034, 1003, 922 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C17H14Cl2O5 369.0297; found 369.0284. 
2-Acetyl-4-(methoxymethoxy)phenyl 5-chloro-2-methoxybenzoate 
(12b). Compound 11 (1.000 g, 5.10 mmol) was dissolved in pyridine (1.5 mL) 
and stirred at rt. 5-Chloro-2-Methoxybenzoyl chloride (0.77 mL, 5.61 mmol) was 
added dropwise, and the solution stirred for 10 min at 75ºC. The solution was 
poured into 3M HCl (6 mL) at 0ºC, and the aqueous layer was extracted with 
EtOAc. The combined organic layers were dried (Na2SO4), filtered, and 
concentrated. The residue was purified by flash chromatography (SiO2, 4:1 
Hexanes:EtOAc to 3:2 Hexanes:EtOAc) to afford 12b (1.36 g, 73%) as a pale 
yellow amorphous solid: 1H NMR (CDCl3, 500 MHz)  8.06 (d, J = 2.75 Hz, 1H), 
7.51 (dd, J = 8.9, 2.75 Hz, 1H), 7.49 (d, J = 3.0 Hz, 1H), 7.24 (dd, J = 8.8, 3.0 Hz, 
1H), 7.13 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 8.9 Hz, 1H), 5.22 (s, 2H), 3.92 (s, 3H), 
3.51 (s, 3H), 2.55 (s, 3H); 13C NMR (CDCl3, 125 MHz)  197.3, 163.3, 158.5, 
154.9, 143.3, 134.1, 132.0, 131.7, 125.3, 124.8, 120.9, 119.8, 117.4, 113.5, 94.67, 
56.3, 56.1, 29.5; IR (film) max 3111, 3080, 3001, 2943, 2905, 2845, 2341, 1751, 
1718, 1690, 1599, 1576, 1489, 1464, 1441, 1400, 1358, 1296, 1275, 1259, 1223, 
1204, 1180, 1153, 1111, 1080, 1040, 1003, 922 cm-1; HRMS(ES+) m/z: [M+Na] 
calcd for C18H17ClO6 387.0611; found 387.0602. 
2-Acetyl-4-(methoxymethoxy)phenyl 2-(trifluoromethyl)benzoate 
(12c). Compound 11 (0.486, 2.48 mmol) was dissolved in pyridine (0.75 mL) and 
stirred at rt. 2-Trifluoromethylbenzoyl chloride (0.40 mL, 2.72 mmol) was added 
dropwise, and the solution stirred for 10 min at 75ºC. The solution was poured 
into 3M HCl (6 mL) at 0ºC, and the aqueous layer was extracted with EtOAc. The 
combined organic layers were dried (Na2SO4), filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 9:1 Hexanes:EtOAc to 1:1 
Hexanes:EtOAc) to afford 12c (0.91 g, 100%) as a pale yellow amorphous solid: 
1H NMR (CDCl3, 500 MHz)  8.16 (d, J = 7.35 Hz, 1H), 7.81 (d, J = 7.50 Hz, 
1H), 7.72 (t, J = 7.35 Hz, 1H), 7.67 (t, J = 7.50 Hz, 1H), 7.51 (d, J = 2.9 Hz, 1H), 
7.28 (dd, J = 8.8, 3.0 Hz, 1H), 7.18 (d, J = 8.8 Hz, 1H), 5.22 (s, 2H), 3.50 (s, 3H), 
2.55 (s, 3H); 13C NMR (CDCl3, 125 MHz)  197.2, 165.2, 155.1, 142.9, 132.0, 
131.6, 131.4, 130.7, 126.74, 126.70, 126.65, 126.61, 124.4, 121.1, 117.8, 94.7, 
56.1, 29.2; IR (film) max 3498, 3366, 3080, 3051, 3001, 2959, 2937, 2907, 2851, 
2829, 2791, 2073, 1998, 1961, 1890, 1846, 1809, 1755, 1693, 1605, 1578, 1487, 
1450, 1418, 1404, 1358, 1315, 1277, 1258, 1219, 1204, 1169, 1153, 1084, 1043, 
1032, 1003, 924 cm-1; HRMS(ES+) m/z: [M+Na] calcd for C18H15F3O5 391.0769; 
found 391.0767. 
2-Acetyl-4-(methoxymethoxy)phenyl 3-(trifluoromethyl)benzoate 
(12d). Compound 11 (4.5 g, 22.94 mmol) was dissolved in pyridine (6.75 mL) 
and stirred at rt. 3-Trifluorobenzoyl chloride (3.73 mL, 25.23 mmol) was added 
dropwise, and the solution stirred for 10 min at 75ºC. The solution was poured 
into 3M HCl (12 mL) at 0ºC, and the aqueous layer was extracted with EtOAc. 
The combined organic layers were dried (Na2SO4), filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 9:1 Hexanes:EtOAc) to 
afford 12d (8.45 g, 99%) as a pale yellow oil: 1H NMR (CDCl3, 500 MHz)  8.47 
(s, 1H), 8.39 (d, J = 7.85 Hz, 1H), 7.90 (d, J = 7.85 Hz, 1H), 7.68 (t, J = 7.85 Hz, 
1H), 7.53 (d, J = 3.0 Hz, 1H), 7.28 (dd, J = 8.8, 3.0 Hz, 1H), 7.15 (d, J = 8.8 Hz, 
1H); 13C NMR (CDCl3, 125 MHz)  197.0, 164.3, 155.1, 143.1, 133.4, 131.2, 
130.19, 130.14, 130.12, 129.3, 127.1, 127.08, 124.7, 121.0, 117.8, 94.7, 56.1, 
29.3; IR (film) max 3472, 3363, 3078, 2959, 2939, 2907, 2829, 2789, 2359, 2341, 
2332, 1747, 1732, 1693, 1682, 1614, 1576, 1495, 1487, 1443, 1418, 1404, 1360, 
1337, 1317, 1296, 1242, 1205, 1173, 1153, 1126, 1070, 1001, 922 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C18H15F3O5 369.0950; found 369.0947. 
1-(2,4-Dichlorophenyl)-3-(2-hydroxy-5-
(methoxymethoxy)phenyl)propane-1,3-dione (13a). Compound 12a (1.7 g, 4.50 
mmol) was dissolved in THF (45 mL) and stirred at rt. Potassium tert-butoxide 
(0.61 g, 5.40 mmol) was added, and the solution stirred for 10 min at rt. The 
solution was poured into 3M HCl (90 mL) at 0ºC, and the aqueous layer was 
extracted with EtOAc. The combined organic layers were dried (Na2SO4), 
filtered, and concentrated. The residue was purified by flash chromatography 
(SiO2, 9:1 Hexanes:EtOAc to 2:3 Hexanes:EtOAc) to afford 13a (1.26 g, 76%) as 
a pale yellow amorphous solid: 1H NMR (CDCl3, 500 MHz) As the enol:  15.26 
(s, 1H), 11.63 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.53 (d, J = 2.0 Hz, 1H), 7.38 (dd, 
J = 8.4, 2.0 Hz, 1H), 7.35 (d, J = 2.9 Hz, 1H), 7.24 (dd, J = 9.05, 2.9 Hz, 1H), 
6.95 (d, J = 9.05 Hz, 1H), 6.74 (s, 1H), 5.13 (s, 2H), 3.50 (s, 1H); 13C NMR 
(CDCl3, 125 MHz) As the enol:  195.6, 174.8, 157.9, 149.6, 137.4, 133.1, 131.9, 
131.2, 130.8, 127.5, 126.2, 119.6, 118.4, 115.3, 98.1, 95.5, 56.0; IR (film) max 
3076, 2995, 2953, 2901, 2845, 2826, 1691, 1643, 1614, 1585, 1556, 1485, 1472, 
1441, 1400, 1366, 1327, 1306, 1286, 1256, 1234, 1188, 1151, 1107, 1080, 1051, 
1011, 922 cm-1; HRMS(ES-) m/z: [M-H] calcd for C17H14Cl2O5 367.0140; found 
367.0140. 
1-(5-Chloro-2-methoxyphenyl)-3-(2-hydroxy-5-
(methoxymethoxy)phenyl)propane-1,3-dione (13b). Compound 13b was 
prepared following the same procedure used in the preparation of compound 13a. 
The residue was purified by flash chromatography (SiO2, 3:1 Hexanes:EtOAc) to 
afford 13b (0.84 g, 65%) as a yellow amorphous solid: 1H NMR (CDCl3, 500 
MHz) As a mixture of tautomers:  15.43 (s, 1H), 11.78 (s, 1H), 11.54 (s, 1H), 
7.99 (d, J = 2.75 Hz, 1H), 7.92 (d, J = 2.75 Hz, 1H), 7.47 (d, J = 2.95 Hz, 1H), 
7.47 (dd, J = 8.9, 2.7 Hz, 1H), 7.43 (dd, J = 8.9, 2.7 Hz, 1H), 7.36 (d, J = 2.8 Hz, 
1H), 7.32 (s, 1H), 7.27 (dd, J = 9, 2.95 Hz, 1H), 7.20 (dd, J = 9, 2.95, 1H), 6.96 
(d, J = 8.9 Hz, 1H), 6.95 (d, J = 8.9 Hz, 1H), 6.94 (d, J = 9 Hz, 1H), 6.89 (d, J = 
8.9 Hz, 1H), 5.16 (s, 2H), 5.13 (s, 2H), 4.59 (s, 2H), 4.00 (s, 3H), 3.67 (s, 3H), 
3.53 (s, 3H), 3.50 (s, 3H); 13C NMR (CDCl3, 125 MHz) As a mixture of 
tautomers:  195.8 (2C), 172.9 (2C), 157.7 (2C), 157.2 (2C), 149.7 (2C), 134.4, 
132.6, 130.7, 129.6, 126.7, 126.2 (2C), 125.8, 123.4 (2C), 119.5, 119.4, 118.8 
(2C), 116.4, 114.9, 113.2, 113.0, 97.9 (2C), 95.6 (2C), 56.0, 55.9, 55.7, 53.9; IR 
(film) max 2997, 2982, 2959, 2949, 2934, 2845, 2824, 1618, 1583, 1564, 1549, 
1489, 1460, 1435, 1400, 1329, 1310, 1286, 1271, 1244, 1223, 1188, 1150, 1113, 
1082, 1070, 1041, 1026, 1005, 922 cm-1; HRMS(ES+) m/z: [M+H] calcd for 
C18H17O6Cl 365.0792; found 365.0783. 
1-(2-Hydroxy-5-(methoxymethoxy)phenyl)-3-(2-
(trifluoromethyl)phenyl)propane-1,3-dione (13c). Compound 13c was prepared 
following the same procedure used in the preparation of compound 13a. The 
residue was purified by flash chromatography (SiO2, 3:1 Hexanes:EtOAc) to 
afford 13c (0.88 g, 80%) as a pale yellow amorphous solid: 1H NMR (CDCl3, 500 
MHz) As the enol:  15.2 (s, 1H), 11.7 (s, 1H), 7.80 (d, J = 7.55 Hz, 1H), 7.64 (m, 
3H), 7.32 (d, J = 2.8 Hz, 1H), 7.23 (dd, J = 9.05, 2.8 Hz, 1H), 6.95 (d, J = 9.05 
Hz, 1H), 6.43 (s, 1H), 5.11 (s, 2H), 3.48 (s, 3H); 13C NMR (CDCl3, 125 MHz) As 
the enol:  195.6, 178.2, 157.9, 149.6, 131.9, 130.6, 130.0, 126.94, 126.90, 
126.86, 126.3, 119.6, 118.3, 115.2, 97.3, 95.4, 55.9; IR (film) max 2955, 2903, 
2827, 1616, 1570, 1487, 1448, 1435, 1402, 1313, 1286, 1256, 1175, 1153, 1136, 
1113, 1095, 1080, 1055, 1036, 1011, 922, 881 cm-1; HRMS(ES+) m/z: [M+H] 
calcd for C18H15F3O5 369.0950; found 369.0934. 
1-(2-Hydroxy-5-(methoxymethoxy)phenyl)-3-(3-
(trifluoromethyl)phenyl)propane-1,3-dione (13d). Compound 13d was 
prepared following the same procedure used in the preparation of compound 13a. 
The residue was purified by flash chromatography (SiO2, 4:1 Hexanes:EtOAc) to 
afford 13d (8.3 g, 94%) as a yellow amorphous solid: 1H NMR (CDCl3, 500 
MHz) As a mixture of tautomers:  15.6 (s, 1H), 11.94 (s, 1H), 11.65 (s, 1H), 8.19 
(s, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.82 (d, J = 7.7 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 
7.44 (d, J = 2.95 Hz, 1H), 7.40 (d, J = 2.95 Hz, 1H), 7.27 (dd, J = 9, 2.95 Hz, 1H), 
7.23 (dd, J = 9, 2.95 Hz, 1H), 6.97 (d, J = 9 Hz, 1H), 6.93 (d, J = 9 Hz, 1H), 6.80 
(s, 1H), 5.18 (s, 2H), 5.14 (s, 2H), 3.53 (s, 3H), 3.51 (s, 3H), 2.63 (s, 2H); 13C 
NMR (CDCl3, 125 MHz) As a mixture of tautomers:  195.6 (2C), 175.4 (2C), 
157.7 (2C), 149.6 (2C), 134.4 (2C), 129.9, 129.4, 128.8, 128.7, 126.4 (2C), 125.9 
(2C), 123.7, 123.6, 119.6, 119.2, 118.5 (2C), 117.1 (2C), 115.4 (2C), 95.5 (2C), 
92.9 (2C), 56.1 (2C), 26.8 (2C); IR (film) max 3076, 2955, 2903, 2827, 1620, 
1576, 1556, 1487, 1448, 1423, 1404, 1337, 1285, 1248, 1190, 1169, 1153, 1128, 
1076, 1040, 1011, 920 cm-1; HRMS(ES+) m/z: [M+H] calcd for 369.0950; found 
369.0945.  
2-(2,4-Dichlorophenyl)-6-hydroxy-4H-chromen-4-one (14a). 
Compound 13a (0.91 g, 2.46 mmol) and a catalytic amount of concentrated 
H2SO4 (120 μL) were dissolved in EtOH (19 mL) at rt. The solution was sealed 
under argon, and exposed to microwave irradiation (25 W, 100°C) for 30 min. 
The reaction mixture was concentrated in vacuo, washed with cold diethyl ether, 
and filtered to provide 14a (0.52 g, 70%) as a white amorphous solid: 1H NMR 
(DMSO-d6, 500 MHz)  10.11 (s, 1H), 7.88 (d, J = 2.05 Hz, 1H), 7.82 (d, J = 8.35 
Hz, 1H), 7.64 (dd, J = 8.35, 2.05 Hz, 1H), 7.56 (d, J = 9 Hz, 1H), 7.34 (d, J = 3 
Hz, 1H), 7.27 (dd, J = 9, 3 Hz, 1H), 6.57 (s, 1H); 13C NMR (DMSO-d6, 125 MHz) 
 176.5, 160.9, 155.1, 149.7, 136.3, 132.8, 132.6, 130.5, 130.0, 128.0, 124.1, 
119.9, 111.4, 107.4; IR (film) max 3452, 1666, 1651, 1634, 1549, 1470, 1410, 
1354, 1275, 1252, 1227, 1107, 1078, 1026, 916 cm-1; HRMS(ES+) m/z: [M+H] 
calcd for C15H8Cl2O3 306.9929; found 306.9916. 
2-(5-Chloro-2-methoxyphenyl)-6-hydroxy-4H-chromen-4-one (14b). 
Compound 14b was isolated as a yellow amorphous solid (0.59 g, 87%) following 
the same procedure used in the preparation of compound 14a: 1H NMR (DMSO-
d6, 500 MHz)  10.03 (s, 1H), 7.92 (d, J = 2.75 Hz, 1H), 7.65 (d, J = 8.9 Hz, 1H), 
7.61 (dd, J = 8.9, 2.75 Hz, 1H), 7.30 (d, J = 3 Hz, 1H), 7.28 (d, J = 9 Hz, 1H), 
7.24 (dd, J = 9, 3 Hz, 1H), 6.86 (s, 1H), 3.92 (s, 3H); 13C NMR (DMSO-d6, 125 
MHz)  177.0, 158.7, 156.4, 154.9, 149.6, 132.1, 128.4, 124.7, 124.0, 123.2, 
121.7, 120.0, 114.5, 111.1, 107.3, 56.5; IR (film) max 3258, 1647, 1626, 1597, 
1566, 1479, 1375, 1358, 1283, 1250, 1236, 1180, 1148, 1126, 1111, 1041, 1014, 
914 cm-1; HRMS(ES+) m/z: [M+H] calcd for C16H11ClO4 303.0424; found 
303.0411. 
6-Hydroxy-2-(2-(trifluoromethyl)phenyl)-4H-chromen-4-one (14c). 
The -ethoxy Michael adduct of compound 14c was isolated as a yellow 
amorphous solid (0.897 mg) following the same procedure used in the preparation 
of compound 14a. Stirring at rt in 2:1 THF: 0.5M aqueous NaOH afforded 14c 
(0.53 g, 65%) as a pale yellow amorpohous solid: 1H NMR (DMSO-d6, 500 MHz) 
 10.1 (s, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.87 (m, 2H), 7.84 (m, 1H), 7.49 (d, J = 
9.0 Hz, 1H), 7.35 (d, J = 3.0 Hz, 1H), 7.27 (dd, J = 9.0, 3.0 Hz, 1H); 13C NMR 
(DMSO-d6, 125 MHz)  176.5, 162.8, 155.1, 149.5, 133.0, 131.51, 131.47, 130.9, 
130.8, 127.0, 126.9, 124.0, 119.6, 110.5, 107.4; IR (film) max 3217, 2961, 2922, 
2851, 1624, 1607, 1574, 1541, 1489, 1472, 1396, 1375, 1360, 1312, 1265, 1232, 
1169, 1130, 1111, 1074, 1036, 968, 916 cm-1; HRMS(ES+) m/z: [M+H] calcd for 
C16H9F3O3 307.0582; found 307.0602. 
6-Hydroxy-2-(3-(trifluoromethyl)phenyl)-4H-chromen-4-one (14d). 
Compound 14d was isolated as a white amorphous solid (0.35 g, 85%) following 
the same procedure used in the preparation of compound 14a: 1H NMR (DMSO-
d6, 500 MHz)  10.03 (s, 1H), 7.90 (dd, J = 7.8, 1.75 Hz, 1H), 7.60 (d, J = 9 Hz, 
1H), 7.54 (dt, J = 7.8, 1.75 Hz, 1H), 7.30 (d, J = 3 Hz, 1H), 7.24 (dd, J = 9, 3 Hz, 
1H), 7.22 (d, J = 7.3 Hz, 1H), 7.13 (dt, J = 7.3, 1 Hz, 1H), 6.90 (s, 1H), 4.19 (q, J 
= 6.9 Hz, 2H), 1.38 (t, J = 6.9 Hz, 3H); 13C NMR (DMSO-d6, 125 MHz)  177.1, 
160.5, 156.9, 154.8, 149.7, 132.8, 129.2, 124.0, 123.2, 120.7, 120.1, 119.9, 113.4, 
110.6, 107.4, 64.2, 14.6; IR (film) max 3439, 3105, 3059, 2976, 2953, 2935, 2889, 
2799, 2725, 2642, 2596, 2581, 1614, 1576, 1566, 1475, 1448, 1416, 1389, 1360, 
1294, 1248, 1202, 1192, 1167, 1129, 1107, 1080, 1036, 928, 906 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C17H14O4 283.0970; found 283.0988. 
tert-Butyl 2-(2,4-dichlorophenyl)-4-oxo-4H-chromen-6-yl carbonate 
(15a). Compound 14a (0.52 g, 1.69 mmol) and di-tert-butyl dicarbonate (0.85 g, 
3.88 mmol) were dissolved in DMF (10 mL) and stirred at rt. A catalytic amount 
of 4-Dimethylaminopyridine (22.67 mg, 0.19 mmol) was added, and the solution 
was stirred for 1 h. The reaction mixture was quenched with H2O (10 mL), and 
extracted with EtOAc (3 x 10 mL). The combined organic layers were washed 
with H2O, brine, dried (Na2SO4), filtered, and concentrated. The residue was 
purified by flash chromatography (SiO2, 7:3 Hexanes:EtOAc) to afford 15a (0.69 
g, 100%) as a white amorphous solid: 1H NMR (CDCl3, 500 MHz)  8.03 (dd, J = 
2.4, 0.9 Hz, 1H), 7.57 (m, 2H), 7.53 (m, 2H), 7.42 (dd, J = 8.3 Hz, 1H), 6.64 (s, 
1H), 1.59 (s, 9H); 13C NMR (CDCl3, 125 MHz)  177.2, 161.7, 153.9, 151.5, 
148.2, 137.5, 133.8, 131.4, 130.8, 130.2, 127.9, 127.6, 124.5, 119.5, 117.6, 112.6, 
27.7 (3C); IR (film) max 3084, 3051, 2982, 2934, 2359, 2341, 1755, 1657, 1626, 
1587, 1551, 1481, 1450, 1391, 1371, 1352, 1271, 1250, 1148, 1130, 1109, 1070, 
1047, 1028, 914 cm-1; HRMS(ES+) m/z: [M+H] calcd for C20H16Cl2O5 407.0453; 
found 407.0439. 
tert-Butyl 2-(5-chloro-2-methoxyphenyl)-4-oxo-4H-chromen-6-yl 
carbonate (15b). Compound 15b was prepared following the same procedure 
used in the preparation of compound 15a. The residue was purified by flash 
chromatography (SiO2, 3:7 Hexanes:EtOAc) to afford 15b (0.74 g, 98%) as a 
white amorphous solid: 1H NMR (CDCl3, 500 MHz)  8.11 (d, J = 2.85 Hz, 1H), 
7.99 (d, J = 2.7 Hz, 1H), 7.68 (d, J = 8.9 Hz, 1H), 7.61 (dd, J = 9, 2.85 Hz, 1H), 
7.54 (dd, J = 9, 2.7 Hz, 1H), 7.37 (s, 1H), 7.09 (d, J = 8.9 Hz, 1H), 4.05 (s, 3H), 
1.69 (s, 9H); 13C NMR (CDCl3, 125 MHz)  178.0, 159.2, 156.6, 153.7, 151.6, 
147.9, 132.0, 128.8, 127.6, 126.0, 124.4, 121.8, 119.4, 117.4, 113.1, 112.6, 84.2, 
56.1, 27.7 (3C); IR (film) max 3115, 3078, 2980, 2941, 2910, 2845, 1759, 1643, 
1624, 1593, 1566, 1479, 1454, 1394, 1371, 1350, 1273, 1252, 1213, 1182, 1150, 
1113, 1080, 1034, 1018, 928 cm-1; HRMS(ES+) m/z: [M+H] calcd for C21H19ClO6 
403.0948; found 403.0959. 
tert-Butyl 4-oxo-2-(2-(trifluoromethyl)phenyl)-4H-chromen-6-yl 
carbonate (15c). Compound 15c was prepared following the same procedure 
used in the preparation of compound 15a. The residue was purified by flash 
chromatography (SiO2, 3:7 Hexanes:EtOAc) to afford 15c (0.66 g, 95%) as a 
white amorphous solid: 1H NMR (CDCl3, 500 MHz)  8.03 (dd, J = 2.0, 1.4 Hz, 
1H), 7.86 (dd, J = 9.0, 1.8 Hz, 1H), 7.67 (m, 3H), 7.51 (m, 2H), 6.51 (s, 1H), 1.59 
(s, 9H); 13C NMR (CDCl3, 125 MHz)  177.3, 164.0, 153.8, 151.5, 148.2, 132.2, 
131.0, 130.9 (2C), 127.9 (2C), 127.19, 127.16, 124.5, 119.6, 117.6, 111.6, 84.3, 
27.6 (3C); IR (film) max 3074, 2982, 2935, 1759, 1657, 1628, 1583, 1574, 1479, 
1452, 1396, 1313, 1285, 1273, 1248, 1148, 1070, 1036, 962, 932, 914 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C21H17F3O5 407.1106; found 407.1114. 
tert-Butyl 4-oxo-2-(3-(trifluoromethyl)phenyl)-4H-chromen-6-yl 
carbonate (15d). Compound 15d was prepared following the same procedure 
used in the preparation of compound 15a. The residue was purified by flash 
chromatography (SiO2, 3:7 Hexanes:EtOAc) to afford 15d (1.33 g, 100%) as a 
white amorphous solid: 1H NMR (CDCl3, 500 MHz)  8.20 (s, 1H), 8.09 (d, J = 8 
Hz, 1H), 8.03 (d, J = 2.9 Hz, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.69 (t, J = 7.8 Hz, 
1H), 7.64 (d, J = 9 Hz, 1H), 7.55 (dd, J = 9, 2.9 Hz, 1H), 6.87 (s, 1H), 1.59 (s, 
9H); 13C NMR (CDCl3, 125 MHz)  177.4, 161.8, 153.5, 151.5, 148.2, 132.5, 
129.8, 129.4, 128.20, 128.17, 127.9, 124.6, 123.2, 123.1, 119.5, 117.6, 107.9, 
84.3, 27.7 (3C); IR (film) max 3462, 3084, 3055, 2982, 2935, 1761, 1649, 1626, 
1576, 1481, 1458, 1396, 1371, 1327, 1281, 1253, 1169, 1150, 1126, 1101, 1078, 
1047, 1016, 924, 906 cm-1; HRMS(ES+) m/z: [M+H] calcd for C21H17F3O5 
407.1106; found 407.1092. 
tert-Butyl 4-oxo-2-phenyl-4H-chromen-6-yl carbonate (15e). 
Commercially available 6-hydroxyflavone (0.55 g, 2.31 mmol) and di-tert-butyl 
dicarbonate (1.16 g, 5.31 mmol) were dissolved in DMF (10 mL) and stirred at rt. 
A catalytic amount of 4-Dimethylaminopyridine (31.0 mg, 0.25 mmol) was 
added, and the solution was stirred for 1 h. The reaction mixture was quenched 
with H2O (10 mL), and extracted with EtOAc (3 x 10 mL). The combined organic 
layers were washed with H2O, brine, dried (Na2SO4), filtered, and concentrated. 
The residue was purified by flash chromatography (SiO2, 7:3 Hexanes:EtOAc) to 
afford 15e (0.78 g, 100%) as a white amorphous solid: 1H NMR (CDCl3, 500 
MHz)  8.02 (d, J = 2.85 Hz, 1H), 7.94 (d, J = 7.65, 1.45 Hz, 1H), 7.93 (d, J = 
8.15, 1.95 Hz, 1H), 7.60 (d, J = 8.9 Hz, 1H), 7.54 (m, 4H), 6.83 (s, 1H), 1.59 (s, 
9H); 13C NMR (CDCl3, 125 MHz)  177.7, 163.6, 153.6, 151.5, 148.0, 131.7, 
131.6, 129.1 (2C), 127.6, 126.3 (2C), 124.6, 119.4, 117.5, 107.1, 84.2, 27.7 (3C); 
IR (film) max 3069, 2982, 2937, 2878, 1807, 1759, 1651, 1626, 1572, 1543, 1497, 
1479, 1454, 1396, 1371, 1358, 1310, 1259, 1213, 1148, 1122, 1070, 1026, 1001, 
951, 932, 908 cm-1; HRMS(ES+) m/z: [M+H] calcd for C20H18O5 339.1233; found 
339.1236. 
3-Amino-2-(2,4-dichlorophenyl)-4-oxo-4H-chromen-6-yl tert-butyl 
carbonate (16a). Compound 15a (0.20 g, 0.49 mmol) and ammonium nitrate 
(0.16 g, 2.0 mmol) were dissolved in anhydrous AcCN (10 mL), and stirred at rt. 
Freshly distilled trifluoroacetic anhydride (0.27 mL, 2.0 mmol) was added 
dropwise, and the reaction mixture stirred for 2 h at rt. The solution was quenched 
with saturated aqueous NaHCO3 (10 mL), and the aqueous layer was then 
extracted with EtOAc (3 x 15 mL). The combined organic layers were washed 
with saturated aqueous NaCl, dried (Na2SO4), filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, Toluene) to afford the nitro 
intermediate as a yellow solid. The solid was subsequently dissolved in EtOH (3.5 
mL) and the solution was purged with argon for 15 min. 10% w/w Pd/C (5.5 mg, 
0.052 mmol) was added, and hydrogen gas was bubbled through the solution for 
30 min. This was followed by stirring under an H2 blanket for 2 h. The reaction 
mixture was filtered through celite to remove catalyst, and rinsed with EtOAc (50 
mL). Rotoevaporation of the filtrate afforded 16a (47.7 mg, 23% over two steps) 
as a pale yellow amorphous solid:  1H NMR (CDCl3, 500 MHz)  8.05 (t, J = 1.65 
Hz, 1H), 7.61 (d, J = 2.0 Hz, 1H), 7.57 (d, J = 8.3 Hz, 1H), 7.46 (d, J = 1.65 Hz, 
2H), 7.44 (dd, J = 8.3, 2.0 Hz, 1H), 3.76 (bs, -NH2, 2H); 
13C NMR (CDCl3, 125 
MHz)  172.6, 153.2, 151.7, 147.2, 141.7, 137.1, 134.7, 132.1, 130.5, 129.2, 
129.1, 127.9, 127.2, 121.7, 119.5, 117.3, 84.1, 27.7 (3C); IR (film) max 3439, 
3333, 3084, 2980, 2930, 2854, 1759, 1643, 1626, 1589, 1566, 1556, 1483, 1394, 
1371, 1319, 1286, 1269, 1244, 1219, 1192, 1144, 1107, 1051, 1024, 905 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C20H17Cl2NO5 422.0562; found 422.0539. 
3-Amino-2-(5-chloro-2-methoxyphenyl)-4-oxo-4H-chromen-6-yl tert-
butyl carbonate (16b). The nitro intermediate for compound 16b was prepared 
following the same procedure used in the preparation of compound 16a, and was 
purified by flash chromatography (SiO2, 9:1 Hexanes:EtOAc). The solid (100 mg, 
0.22 mmol) was dissolved in THF (4 mL) and the solution was purged with argon 
for 15 min. Pt2O (15 mg, 15% w/w) was added, and hydrogen gas was bubbled 
through the solution for 30 min. This was followed by stirring under an H2 
blanket for 3 h. The reaction mixture was filtered through celite to remove 
catalyst, and rinsed with EtOAc (100 mL). Purification by preparative TLC (7:3 
Hexanes:EtOAc) afforded 16b (51.5 mg, 63% over two steps) as a yellow 
amorphous solid: 1H NMR (CDCl3, 500 MHz)  8.05 (d, J = 3.0 Hz, 1H), 7.57 (d, 
J = 2.6 Hz, 1H), 7.48 (d, J = 9.1 Hz, 1H), 7.46 (t, J = 3.0 Hz, 1H), 7.45 (t, J = 2.7 
Hz, 1H), 7.02 (d, J = 8.9 Hz, 1H), 4.01 (bs, -NH2, 2H), 3.92 (s, 3H), 1.59 (s, 9H); 
13C NMR (CDCl3, 125 MHz)  172.8, 154.9, 153.4, 151.7, 147.1, 142.1, 131.4, 
130.4, 129.6, 127.0, 126.3, 122.7, 121.5, 119.4, 117.2, 113.2, 84.1, 56.4, 27.7 
(3C); IR (film) max 3435, 3348, 3107, 3072, 3065, 2980, 2934, 2851, 1759, 1622, 
1589, 1566, 1485, 1464, 1410, 1394, 1371, 1283, 1269, 1254, 1242, 1182, 1146, 
1070, 1047, 1024, 930, 901 cm-1; HRMS(ES+) m/z: [M+H] calcd for 
C21H20ClNO6; found 418.1058. 
3-Amino-4-oxo-2-(2-(trifluoromethyl)phenyl)-4H-chromen-6-yl tert-
butyl carbonate (16c). Compound 16c was prepared following the same 
procedure used in the preparation of compound 16a. The nitro intermediate was 
purified by flash chromatography (SiO2, 50:1 Toluene:EtOAc). 16c (5.0 mg, 2.6% 
over two steps) was afforded as a yellow amorphous solid: 1H NMR (CDCl3, 500 
MHz)  8.06 (dd, J = 2.2, 0.9 Hz, 1H), 7.90 (d, J = 7.8 Hz, 1H), 7.75 (d, J = 0.9 
Hz, 1H), 7.74 (dd, J = 2.1, 0.9 Hz, 1H), 7.68 (m, 1H), 7.45 (m, 2H); 13C NMR 
(CDCl3, 125 MHz)  172.7, 153.0, 151.7, 147.2, 142.8, 132.5, 131.3, 130.6, 
129.9, 129.6, 128.6, 127.5, 127.2, 121.7, 119.5, 117.2, 84.1, 27.7 (3C); IR (film) 
max 3448, 3348, 3072, 2980, 2930, 2856, 1759, 1639, 1605, 1589, 1568, 1483, 
1462, 1450, 1410, 1396, 1371, 1315, 1286, 1265, 1244, 1219, 1196, 1173, 1146, 
1111, 1082, 1055, 1036, 1024, 1009, 962, 928, 903cm-1; HRMS(ES+) m/z: [M+H] 
calcd for C21H18F3NO5 422.1215; found 422.1209. 
3-Amino-4-oxo-2-(3-(trifluoromethyl)phenyl)-4H-chromen-6-yl tert-
butyl carbonate (16d). Compound 16d was prepared following the same 
procedure used in the preparation of compound 16a. The nitro intermediate was 
purified by flash chromatography (SiO2, Toluene). 16d (11.8 mg, 23% over two 
steps) was afforded as a pale yellow amorphous solid: 1H NMR (CDCl3, 500 
MHz)  8.20 (s, 1H), 8.15 (d, J = 7.7 Hz, 1H), 8.05 (d, J = 2.8 Hz, 1H), 7.73 (d, J 
= 7.8 Hz, 1H), 7.69 (t, J = 7.75 Hz, 1H), 7.54 (d, J = 9.1 Hz, 1H), 7.49 (dd, J = 
9.1, 2.8 Hz, 1H), 4.08 (-NH2), 1.59 (s, 9H); 
13C NMR (CDCl3, 125 MHz)  172.9, 
152.9, 151.6, 147.3, 142.5, 133.5, 130.7, 129.6, 128.4, 127.3, 126.31, 126.28, 
124.40, 124.37, 121.3, 119.4, 117.3, 84.2, 27.7 (3C); IR (film) max 3337, 2982, 
2930, 2853, 1759, 1717, 1684, 1636, 1622, 1589, 1568, 1541, 1506, 1485, 1458, 
1396, 1371, 1331, 1285, 1269, 1242, 1167, 1148, 1099, 1074, 1028, 1013, 928, 
903 cm-1; HRMS(ES+) m/z: [M+H] calcd for C21H18F3NO5 422.1215; found 
422.1233. 
3-Amino-4-oxo-2-phenyl-4H-chromen-6-yl tert-butyl carbonate (16e). 
Compound 16e was prepared following the same procedure used in the 
preparation of compound 16a. The nitro intermediate was purified by flash 
chromatography (SiO2, 8:2 Hexanes:EtOAc). 16e (170.3 mg, 82% over two steps) 
was afforded as a pale yellow amorphous solid: 1H NMR (CDCl3, 500 MHz)  
8.03 (d, J = 2.8 Hz, 1H), 7.92 (d, J = 1.4 Hz, 1H), 7.91 (d, J = 7.2 Hz, 1H), 7.55 
(m, 3H), 7.51 (d, J = 9.1 Hz, 1H), 7.46 (dd, J = 9.1, 2.9 Hz, 1H), 4.07 (bs, -NH2, 
2H), 1.58 (s, 9H); 13C NMR (CDCl3, 125 MHz)  172.8, 152.9, 151.7, 147.1, 
144.5, 133.0, 132.5, 129.8, 129.3, 129.0, 127.8, 127.6, 126.9, 121.4, 119.4, 117.1, 
84.1, 27.6 (3C); IR (film) max 3427, 3340, 3205, 3066, 2982, 2934, 1759, 1663, 
1622, 1587, 1564, 1537, 1481, 1456, 1404, 1371, 1281, 1242, 1217, 1188, 1144, 
1076, 1047, 1022, 924, 901 cm-1; HRMS(ES+) m/z: [M+H] calcd for C20H19NO5 
354.1342; found 354.1358. 
3-Amino-2-(2-methoxyphenyl)-4-oxo-4H-chromen-6-yl tert-butyl 
carbonate (16f). Utilizing compound 15b as starting material, compound 16f was 
prepared following the same procedure used in the preparation of compound 16a. 
The nitro intermediate was purified by flash chromatography (SiO2, 9:1 
Hexanes:EtOAc). 16f (31.7 mg, 17% over two steps) was afforded as a yellow 
amorphous solid: 1H NMR (CDCl3, 500 MHz) As a mixture of conformational 
isomers:  8.05 (t, J = 2.9 Hz, 1H), 7.57 (d, J = 2.65 Hz, 1H), 7.46 (m, 3H), 7.14 
(t, J = 8.3 Hz, 1H), 7.08 (d, J = 8.4 Hz, 1H), 7.02 (d, J = 1H), 4.01 (bs, -NH2, 2H), 
3.92 (s, 3H), 3.91 (s, 3H), 1.59 (s, 9H); As a mixture of conformational isomers: 
13C NMR (CDCl3, 125 MHz)  172.8, 172.7, 156.4, 154.9, 153.4, 153.3, 151.7, 
151.6, 147.1, 147.0, 142.1, 131.8, 131.4, 130.7, 130.4, 129.6, 129.3, 127.0, 126.7, 
126.3, 122.7, 121.6, 121.5, 121.4, 121.2, 121.1, 119.4, 117.2, 117.1, 113.2, 111.8, 
84.0, 56.3, 55.9, 27.7 (3C); IR (film) max 3435, 3348, 3070, 2980, 2935, 2872, 
2851, 1759, 1622, 1566, 1483, 1462, 1433, 1408, 1396, 1371, 1254, 1242, 1182, 
1146, 1070, 1047, 1022, 978, 930, 901 cm-1; HRMS(ES+) m/z: [M+H] calcd for 
C21H21NO6 384.1447; found 384.1463. 
N-(2-(2,4-Dichlorophenyl)-6-hydroxy-4-oxo-4H-chromen-3-
yl)acetamide (17a). Compound 16a (7.7 mg, 0.018 mmol) was dissolved in 
anhydrous AcCN (0.15 mL) and stirred at rt. N,N-Diisopropylethylamine (3.81 
μL, 0.022 mmol) was added dropwise, followed by acetyl chloride (1.68 μL, 
0.024 mmol), and stirred at rt for 1.5 h. The solution was brought up in EtOAc (5 
mL), and washed with H2O, saturated aqueous NaCl, dried, and concentrated. The 
residue was purified by flash chromatography (SiO2, 8:2 Hexanes:EtOAc to 100% 
EtOAc) to afford  the N-acylated intermediate as a pale yellow solid. The solid 
was subsequently dissolved in MeOH (0.15 mL), and stirred at rt. HCl gas was 
bubbled through solution for 10 seconds, and the solution stirred for 5 min, 
followed by rotoevaporation. The residue was purified by flash chromatography 
(SiO2, 1:1 Hexanes:EtOAc) to afford 17a (2.4 mg, 28% over two steps) as a pale 
yellow amorphous solid: 1H NMR (MeOD, 500 MHz)  7.66 (d, J = 1.9 Hz, 1H), 
7.53 (d, J = 8.3 Hz, 1H), 7.48 (m, 3H), 7.29 (dd, J = 9.1, 3.0 Hz, 1H), 1.94 (s, 
3H); 13C NMR (MeOD, 125 MHz)  176.7, 173.3, 161.7, 157.1, 151.7, 138.5, 
135.4, 133.1, 131.1, 130.1, 128.7, 125.44, 125.35, 121.3, 121.0, 109.1, 22.5; IR 
(film) max 3269, 2953, 2924, 2854, 1740, 1697, 1670, 1622, 1591, 1556, 1487, 
1472, 1456, 1387, 1362, 1337, 1256, 1236, 1204, 1182, 1151, 1101, 1082, 1116, 
970, 912 cm-1; HRMS(ES+) m/z: [M+Na] calcd for C21H11Cl2NO4 385.9963; 
found 385.9943.  
N-(2-(5-Chloro-2-methoxyphenyl)-6-hydroxy-4-oxo-4H-chromen-3-
yl)acetamide (17b). Compound 17b was prepared following the same procedure 
used in the preparation of compound 17a. The N-acylated intermediate was 
purified by flash chromatography (SiO2, 7:3 Hexanes:EtOAc to 100% EtOAc). 
Purification in the final step by preparative TLC (SiO2, 1:9 Hexanes:EtOAc) 
afforded 17b (14.6 mg, 33% over two steps) as a pale yellow amorphous solid: 1H 
NMR (MeOD, 500 MHz) As a mixture of conformational isomers:  7.48 (m, 
4H), 7.27 (dd, J = 9.0, 3.0 Hz, 1H), 7.15 (d, J = 9.0 Hz, 1H), 3.84 (s, 3H), 1.95 
(2s, 3H); 13C NMR (MeOD, 125 MHz)  176.7, 173.3, 161.9, 157.4, 156.9, 151.8, 
133.2, 130.9, 126.5, 125.4, 125.1, 123.6, 121.0, 114.5, 109.1, 56.9, 30.6, 22.5; IR 
(film) max 2930, 2851, 1655, 1637, 1610, 1574, 1543, 1483, 1472, 1435, 1404, 
1391, 1356, 1313, 1281, 1259, 1248, 1227, 1204, 1171, 1148, 1128, 1111, 1070, 
1040, 1018, 984, 933 cm-1; HRMS(ES+) m/z: [M+H] calcd for C18H14ClNO5 
360.0639; found 360.0621. 
N-(6-Hydroxy-4-oxo-2-(2-(trifluoromethyl)phenyl)-4H-chromen-3-
yl)acetamide (17c). Compound 17c was prepared following the same procedure 
used in the preparation of compound 17a. The N-acylated intermediate was 
purified by flash chromatography (SiO2, 6:4 Hexanes:EtOAc to 100% EtOAc). 
Purification in the final step by preparative TLC (SiO2, 3:7 Hexanes:EtOAc) 
afforded 17c (2.1 mg, 49% over two steps) as a pale yellow amorphous solid: 1H 
NMR (MeOD, 500 MHz)  7.91 (m, 1H), 7.75 (m, 1H), 7.66 (m, 1H), 7.48 (d, J = 
3.0 Hz, 1H), 7.45 (d, J = 9.0 Hz, 1H), 7.30 (dd, J = 9.0, 3.0 Hz, 1H), 1.94 (s, 3H); 
13C NMR (MeOD, 125 MHz)  176.7, 173.7, 163.3, 157.1, 151.5, 133.3, 132.5, 
131.9, 129.6, 128.24, 128.21, 126.7, 125.5, 125.3, 120.9, 109.2, 30.6, 22.4; IR 
(film) max 3402, 3256, 3043, 3011, 2955, 2924, 2853, 2359, 2341, 1624, 1576, 
1558, 1522, 1474, 1404, 1369, 1315, 1294, 1277, 1238, 1207, 1173, 1132, 1113, 
1063, 1036, 1005, 966, 939 cm-1; HRMS(ES+) m/z: [M+H] calcd for 
C18H12F3NO4 364.0797; found 364.0789. 
N-(6-hydroxy-4-oxo-2-(3-(trifluoromethyl)phenyl)-4H-chromen-3-
yl)acetamide (17d). Compound 17d was prepared following the same procedure 
used in the preparation of compound 17a. The N-acylated intermediate was 
purified by flash chromatography (SiO2, 7:3 Hexanes:EtOAc to 100% EtOAc). 
Purification in the final step by preparative TLC (SiO2, 1:1 Hexanes:EtOAc) 
afforded 17d (5.0 mg, 51% over two steps) as a pale yellow amorphous solid: 1H 
NMR (MeOD, 500 MHz)  8.09 (s, 1H), 8.05 (d, J = 7.8 Hz), 7.86 (d, J = 7.8 Hz, 
1H), 7.75 (t, J = 7.8 Hz, 1H), 7.59 (d, J = 9.1 Hz, 1H), 7.47 (d, J = 3.0 Hz, 1H), 
7.31 (dd, J = 9.1, 3 Hz), 2.05 (s, 3H); 13C NMR (MeOD, 125 MHz)  177.0, 
173.7, 162.3, 157.1, 151.5, 134.4, 133.1, 130.9, 128.7, 126.30, 126.27, 125.4, 
121.1, 119.7, 109.1, 78.3, 30.6, 22.7; IR (film) max 3367, 3248, 2922, 2853, 1717, 
1699, 1666, 1651, 1634, 1622, 1574, 1558, 1539, 1516, 1472, 1456, 1385, 1367, 
1327, 1294, 1269, 1229, 1173, 1117, 1097, 1082, 1003, 912 cm-1; HRMS(ES+) 
m/z: [M+H] calcd for C18H12F3NO4 364.0707; found 364.0769. 
N-(6-hydroxy-4-oxo-2-phenyl-4H-chromen-3-yl)acetamide (17e). 
Compound 17e was prepared following the same procedure used in the 
preparation of compound 17a. The N-acylated intermediate was purified by flash 
chromatography (SiO2, 7:3 Hexanes:EtOAc to 100% EtOAc). Purification in the 
final step by preparative TLC (SiO2, 7:3 Hexanes:EtOAc) afforded 17e (29.7 mg, 
60% over two steps) as an orange amorphous solid: 1H NMR (MeOD, 500 MHz) 
 7.78 (d, J = 7.5 Hz, 1H), 7.77 (d, J = 8.05 Hz, 1H), 7.55 (m, 4H), 7.46 (d, J = 
2.95 Hz, 1H), 7.29 (dd, J = 9.05, 3.0 Hz, 1H), 2.06 (s, 3H); 13C NMR (MeOD, 
125 MHz)  177.2, 173.9, 164.4, 156.9, 151.6, 133.3, 132.3, 129.8 (2C), 129.5 
(2C), 125.2, 125.1, 121.0, 119.1, 109.1, 22.7; IR (film) max 3418, 3192, 2928, 
2853, 1661, 1616, 1568, 1556, 1539, 1520, 1495, 1472, 1447, 1404, 1367, 1312, 
1294, 1269, 1236, 1204, 1178, 1146, 1111, 1076, 1026, 1001, 966, 924 cm-1; 
HRMS(ES+) m/z: [M+H] calcd for C17H13NO4 296.0923; found 296.918. 
N-(6-Hydroxy-2-(2-methoxyphenyl)-4-oxo-4H-chromen-3-
yl)acetamide (17f). Compound 17f was prepared following the same procedure 
used in the preparation of compound 17a. The N-acylated intermediate was 
purified by flash chromatography (SiO2, 7:3 Hexanes:EtOAc to 100% EtOAc). 
Purification in the final step by preparative TLC (SiO2, 2:8 Hexanes:EtOAc) 
afforded 17f (55.8 mg, 55% over two steps) as a pale yellow amorphous solid: 1H 
NMR (MeOD, 500 MHz) As a mixture of conformational isomers:  7.67 (d, J = 
7.7 Hz, 1H), 7.50 (m, 1H), 7.45 (m, 3H), 7.24 (m, 1H), 7.13 (d, J = 8.3 Hz, 1H), 
7.04 (t, J = 7.7 Hz, 1H), 3.87 (2s, 3H), 1.95 (bs, 3H); 13C NMR (MeOD, 125 
MHz) As a mixture of conformational isomers:  163.7, 161.7, 158.3, 156.4, 
151.7, 151.6, 135.4, 133.5, 133.0, 131.7, 131.0, 130.6, 125.6, 124.7, 122.4, 121.8, 
121.3, 121.1, 120.75, 120.69, 114.3, 113.3, 112.6, 108.9, 108.5, 56.7, 56.3, 30.3, 
22.3; IR (film) max 3493, 3246, 3084, 3011, 2945, 2841, 2565, 2419, 2351, 2243, 
2135, 1651, 1614, 1574, 1479, 1454, 1435, 1416, 1371, 1285, 1254, 1211, 1180, 
1165, 1150, 1117, 1105, 1082, 1049, 1020, 972, 935, 879 cm-1; HRMS(ES+) m/z: 
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